Profiles

Anna King

Professor Anna King

Anna King

Professor (Research)
Wicking Dementia Research & Education Centre

Room 422D , Medical Science Precinct

+61 3 6226 4817 (phone)

A.E.King@utas.edu.au

Investigating the neurodegenerative diseases of aging

Investigating the neurodegenerative diseases of aging

Professor Anna King's research focuses on investigating the neurodegenerative diseases of aging, including frontotemporal dementia, Alzheimer's disease and motor neuron disease. She is particularly interested in determining the mechanisms by which the connections between nerve cells are lost in these diseases.

'The clinical symptoms of most of these neurodegenerative diseases are not due to cell loss or the pathology, but the loss of connections between nerve cells, so they can no longer 'talk' to each other,' said Professor King.

'Nerve cells are very specialized and unique cells. They have a very distinct shape, which is important for the way they function. The shape of a nerve cell is dominated by the long nerve processes, which, like electrical wires, are responsible for connecting nerve cells with each other. What many people don't realize is that sometimes over 99% of the cell is in these nerve processes, yet we really don't know much about how they function,' Professor King said.

Professor King says a lot of her work is at a very cellular level.

'I do a lot of cell culture work where I look at the way cells respond to different things. I would consider myself a cell biologist. My research also extends into animal models and human tissue as this is important in translation.'

Professor King says that in order to understand disease, it is important to understand normal function.

'Sometimes we need to take a step backwards to do some basic research to see how nerve cells work and interact with each other. We can try and treat pathology but if we don't really know how that pathology has come about, we're not really getting rid of the cause of it…'

Professor King is also interested in why these neurodegenerative diseases are related to ageing.

'Some people have mutations that cause these diseases, but they don't develop the disease while they're young, instead the disease develops as they get older.

We need to answer the question of why there is a connection between neurodegenerative diseases and ageing and what's changing in healthy ageing, and what the difference is when we get disease,' said Professor King.

Professor King works for The Wicking Dementia Research and Education Centre, which is a multi-disciplinary group that brings together all aspects of dementia research, care and education. It's part of the University of Tasmania College of Health and Medicine and receives its core funding from the JO & JR Wicking Trust.

'In the Wicking Centre, we're interested in educating people about dementia' Professor King said. 'It's very important that those involved with working with people with dementia, understand these neurodegenerative diseases, what causes them, why people behave the way they do and the special needs they have. We're keen to combine our research with educating the public and people in care situations,' she said.

'These diseases are becoming more prevalent now because we have treatments for a lot of the other diseases that people used to die from. So people are living longer. These diseases are becoming more prominent in our community and we are really not prepared for this,' said Professor King.

She says there is some evidence now that for diseases such as Alzheimer's disease, a proportion of cases could be prevented or delayed by modifying lifestyle factors throughout life. Risk prevention, in other words.

'There's a lot more focus on lifestyle factors now. I think that's a very important area. I feel that if we can do something there, then we should be doing it.'

'At Wicking we're looking at whether cognitive stimulation can improve outcomes in terms of the symptoms of the disease. For example, using your brain in new ways to build up your resilience for when you get older and you're losing those connections,' Professor King said.

The higher the education you have, the lower your risk.

However, ultimately there will still be some people who need treatment and care, Professor King says.

The brain can withstand a lot of pathology before we see anything happening. We need to be catching things earlier.

We know now that although symptoms occur at a certain (advanced) age, there is a long period before the disease actually presents, during which we're developing the pathology. This can go on for fifteen years or so before we actually develop clinical symptoms. It's important to be looking in those early stages for strategies to help people,' Professor King said.

'Once you've lost cognitive function, you can't really get it back.'

Professor Anna King is an NHMRC Boosting Dementia Research Leadership Fellow and Associate Director (Research) at the Wicking Dementia Research and Education Centre in the College of Health and Medicine. She leads an active research team in the field of neurodegenerative disease and ageing, including Alzheimer's disease, frontotemporal dementia and amyotrophic lateral sclerosis. She works alongside other University of Tasmania researchers to investigate basic pathological mechanisms of disease, preventative and therapeutic strategies as well as the development of biomarkers to determine brain health.

Biography

Professor King obtained her honours degree from the University of Durham in the UK before training in molecular biology at the Heart Research Institute in Sydney. She undertook her PhD in pathology of neurodegenerative disease at the University of Tasmania. Following her doctoral studies she was awarded postdoctoral fellowships from the Motor Neuron Disease Research Institute of Australia (2008-2011) and Alzheimer's Australia Dementia Research Foundation (2011-2013). In 2017 she was awarded an NHMRC Dementia Fellowship and took on a leadership role as Associate Director (Research) for the Wicking Dementia Centre. She is involved in engaging with the community through the Wicking Centre’s Massive Open Online Courses (MOOCs) including the Understanding Dementia and Preventing Dementia MOOC and also teaches in the Bachelor of Dementia Care

Professor King's key research interest is in investigating how the connections between nerves cells are lost in neurodegenerative disease with a focus on protective strategies. Since starting her PhD in 2004 she has authored more than 50 peer-reviewed papers in well-regarded Neuroscience journals such as Acta Neuropathologica, Neurobiology of Ageing and Human Molecular Genetics. These papers have been cited over 1000 times. Her research has attracted over $4.5M in funding including NHMRC and ARC grants and fellowships.

Career summary

Qualifications

PhD, University of Tasmania, Australia. 2008 Thesis: Unravelling the Cellular Pathology leading to Neurodegeneration in Motor Neuron Disease
BSc (Hons), University of Durham, UK. 1988

Memberships

Professional practice

Member of the International Society of Frontotemporal Dementias (2018-current)
Member of Dementia Australia Scientific Committee (2017- current)
NHMRC National Institute of Dementia Research (NNIDR) member (2017- current)
Member of Pan Asian Committee for Treatment and Research in Amyotrophic Lateral Sclerosis (PACTALS) (2014-current)
Member of the Australasian Neuroscience Society (2005 - current)
Member of Alzheimer's Association (2014 - 2017)
Member of the Brain Foundation (2014 - 2016)
Member of the Australian Society for Medical Research (ASMR) (2007- 2010)

Other

Chair of Organizing Committee for Australian Dementia Forum 2019
Local Organizing Committee National Neurotrauma Meeting 2014-2016
Local Organizing Committee ANS 2016
Grant reviewer NHMRC, MRC, HRCNZ, DARF

Administrative expertise

Associate Director (Research) Wicking Dementia Centre (2017-current)
Academic Coordinator Wicking Centre (2016-current)
College of Health and Medicine Research Committee (2017-current)
Co-chair Lab Management Committee for the University of Tasmania Medical Sciences Precinct (2017-current)
Animal Ethics Committee member (2013-2016)

Teaching

Neurodegenerative disease, Dementia, Motor Neuron Disease

Teaching expertise

Neurodegenerative disease, Dementia, Motor Neuron Disease
Unit Design and Co-ordinator, The Art & Science of Clinical Trials (CAD303).
Lecturer and past co-ordinator, Neuroscience Research in Dementia (CAD301)\
Lecturer, Neuroscience (CHP312)
Lecturer, Fundamentals of Clinical Science (CAM304)

Research Invitations

Invited Symposium Speaker at Australasian Neuroscience Society Conference 2018
Invited Keynote speaker at Taishan Medical University, Shandong Province, China (May 2017)
Invited speaker at 6^th Australia-China International Biomedical Research Conference, Xian, China (October 2017)
Keynote Speaker at the Wicking Dementia Centre Public Forum (2016)
Guest-editor a special issue in Journal of Chemical Neuroanatomy titled ‘Axon Pathology and Repair,’ published in August 2016
Invited Speaker at Cell Architecture in Development and Disease symposium (2015)
Invited Speaker at the Australian and New Zealand National Microfluidics Conference (2014)

View more on Professor Anna King in WARP

Expertise

Primary Cell Culture and live imaging
Molecular and biochemical techniques including viral transduction
Biomarkers detection
Post mortem human tissue histology
Animal Models of neurodegenerative disease including intraocular injection

Research Themes

Anna's research closely aligns with the University's research theme of Better Health as well as the Dementia flagship in the College of Health and Medicine. Her interests lie in investigating the changes in the nervous system that accompany normal ageing as well as the development of age-related neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia and amyotrophic lateral sclerosis. There is accumulating evidence that the clinical symptoms of these diseases are the result of the loss of connectivity between the nerves cells but there is little understanding of the mechanisms by which nerve cells loose connectivity in disease and the contribution that ageing plays to this. Additionally, harnessing the ability of the brain to renew connections (brain plasticity) in ageing and disease may help prevent this loss.

Anna's research focuses predominantly on the axon, the nerve process that is responsible for conducting signals between nerve cells, as well as the connections formed by the axon at the synapse. The key themes of her research are:

Axonal plasticity, pathology and the mechanisms by which axons degenerate in neurodegenerative disease and injury.
The role of pathogenic proteins, such as TDP-43, C9ORF72, and β-amyloid in axon and synaptic function
Excitotoxic mechanism of neurodegeneration
Signalling mechanisms between the cell soma and the axon, including axonal transport
The role of the neuronal cytoskeleton, including neurofilaments and microtubules in axonal and synaptic function as well as neurodegeneration.
The role of glial cells, such as oligodendrocytes, microglia and astrocytes, in maintaining axon function.
Development of blood biomarkers to indicate nerve cell health in the brain

Collaboration

Professor King collaborates nationally and internationally with researchers in her field including:

Prof Julie Atkin (Macquarie University) on research projects in motor neuron disease and frontotemporal dementia. Their joint research has resulted in a number of publications including the highly cited first article to describe the potential role of the C9ORF72 protein in membrane trafficking (M A Farg, et al., 2014 Hum Mol Genet).

Dr Anthony Cook (University of Tasmania) and Professor Alex Hewitt (University of Tasmania), to develop the use of stem cell technology to investigate mechanisms of neurodegenerative disease.

Prof Michael Breadmore (Chemistry, University of Tasmania), Professor Rosanne Guijt (Deakin), Prof Tracey Dickson (Menzies Institute for Medical Research, University of Tasmania) on projects to develop microfluidic technology for dementia research including development of point of care biomarker devices.

Current projects

Axon Degeneration and Axon Protection in Neurodegenerative disease and injury (funded by NHMRC 2014- current)
Biomarkers of Brain Health (funded by NHMRC 2018-2021)
The Tasmanian Heathy Brain Project (funded by NHMRC 2015-2020)
Towards axon protection in ALS (MNDRIA 2018-2019)
Staying connected: determining targets to protect neuronal circuitry in ALS (2017-2018)
Developing a protocol to predicting health outcomes through oral microbes. Lead by Dr Silvana Bettiol
Does plasticity drive Alzheimer’s disease and can sleep help? Judith Jane Mason ANZ trustees. Lead by Dr Matthew Kirkcaldie
Could gut microbiota influence cognitive decline and Alzheimer's disease? Ubiome. Lead by Dr Jenna Ziebell

Fields of Research

Cellular nervous system (320902)
Neurology and neuromuscular diseases (320905)
Central nervous system (320903)
Neurosciences (320999)
Cell development, proliferation and death (310102)
Health promotion (420603)
Aged health care (420301)
Geriatrics and gerontology (320210)
Medical biotechnology diagnostics (incl. biosensors) (320602)
Preventative health care (420605)
Residential client care (420320)
Cognitive neuroscience (520203)
Gene and molecular therapy (320601)
Behavioural neuroscience (520202)
Proteomics and intermolecular interactions (excl. medical proteomics) (310109)
Autonomic nervous system (320901)
Other chemical sciences (349999)
Pharmaceutical sciences (321405)
Peripheral nervous system (320906)
Implementation science and evaluation (420312)
Continuing and community education (390301)
Analytical chemistry (340199)
Aboriginal and Torres Strait Islander public health and wellbeing (450417)
Epidemiology (420299)
Separation science (340109)
Microbiology (310799)
Dentistry (320399)
Clinical chemistry (incl. diagnostics) (320202)
Cell metabolism (310103)
Medical microbiology (320799)
Plant physiology (310806)
Instrumental methods (excl. immunological and bioassay methods) (340105)
Microbial genetics (310704)
Biochemistry and cell biology (310199)
Ophthalmology (321201)
Machine learning (461199)
Digital health (420302)
Cardiology (incl. cardiovascular diseases) (320101)
Analytical biochemistry (310101)
Biomechanical engineering (400303)
Medical infection agents (incl. prions) (320702)
Basic pharmacology (321401)
Artificial intelligence (460299)
Primary health care (420319)
Microtechnology (401410)
Clinical pharmacology and therapeutics (321402)
Animal physiology - systems (310910)
Flexible manufacturing systems (401403)
Microbial ecology (310703)
Nutrition and dietetics (321099)
Pathology (excl. oral pathology) (320220)
Crop and pasture biochemistry and physiology (300404)
Health services and systems (420399)
Aboriginal and Torres Strait Islander health promotion (450408)
Genomics and transcriptomics (310204)
Neurogenetics (310511)
Sensor technology (incl. chemical aspects) (340108)
Biomedical engineering (400399)
Cell neurochemistry (310104)
Computer vision (460304)
Behavioural epidemiology (420201)
Oral medicine and pathology (320307)
Animal physiology - cell (310909)
Characterisation of biological macromolecules (340403)
Applications in health (460102)
Deep learning (461103)
Intensive care (320212)
Systems physiology (320803)
Cellular immunology (320404)

Research Objectives

Clinical health (200199)
Treatment of human diseases and conditions (200105)
Diagnosis of human diseases and conditions (200101)
Health related to ageing (200502)
Prevention of human diseases and conditions (200104)
Public health (excl. specific population health) (200499)
Health education and promotion (200203)
Expanding knowledge in the biomedical and clinical sciences (280103)
Preventive medicine (200412)
Mental health (200409)
Expanding knowledge in the health sciences (280112)
Expanding knowledge in the chemical sciences (280105)
Expanding knowledge in the biological sciences (280102)
Determinants of health (200201)
Efficacy of medications (200102)
Behaviour and health (200401)
Dental health (200402)
Ageing and older people (230102)
Fabricated metal products (240799)
Nutrition (200410)
Food safety (200405)
Expanding knowledge in the environmental sciences (280111)
Scientific instruments (241003)
Aboriginal and Torres Strait Islander determinants of health (210301)
Nursing (200307)
Human pharmaceutical products (240899)
Other plant production and plant primary products (269999)
Management of water consumption by animal production (100104)
Coastal and estuarine systems and management (180299)
Human pharmaceutical treatments (240803)
Health inequalities (200204)
Energy storage (excl. hydrogen and batteries) (170304)
Injury prevention and control (200408)
Disability and functional capacity (200403)
Evaluation of health outcomes (200202)

Publications

Total publications

146

Journal Article

(83 outputs)

Year	Citation	Altmetrics
2023	Kabir F, Atkinson R, Cook AL, Phipps AJ, King AE, 'The role of altered protein acetylation in neurodegenerative disease', Frontiers in Aging Neuroscience, 14 pp. 1-24. ISSN 1663-4365 (2023) [Refereed Article] DOI: 10.3389/fnagi.2022.1025473 [eCite] [Details] Co-authors: Kabir F; Atkinson R; Cook AL; Phipps AJ Tweet
2023	Stellon D, Talbot J, Hewitt AW, King AE, Cook AL, 'Seeing neurodegeneration in a new light using genetically encoded fluorescent biosensors and iPSCs', International Journal of Molecular Sciences, 24, (2) pp. 1-26. ISSN 1422-0067 (2023) [Refereed Article] DOI: 10.3390/ijms24021766 [eCite] [Details] Co-authors: Stellon D; Talbot J; Hewitt AW; Cook AL Tweet
2022	Alty JE, Bai Q, Li R, Lawler K, St George RJ, et al., 'The TAS Test project: a prospective longitudinal validation of new online motor-cognitive tests to detect preclinical Alzheimer's disease and estimate 5-year risks of cognitive decline and dementia', BMC Neurology, 22 Article 266. ISSN 1471-2377 (2022) [Refereed Article] DOI: 10.1186/s12883-022-02772-5 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Alty JE; Bai Q; Li R; Lawler K; St George RJ; Hill E; Bindoff A; Garg S; Wang X; Huang G; Zhang K; Rudd KD; Bartlett L; Goldberg LR; Collins JM; Hinder MR; Vickers JC Tweet
2022	Alty JE, Bindoff A, Stuart K, Hill E, Collins J, et al., 'Sex-specific protective effects of cognitive reserve on age-related cognitive decline: A 5-Year prospective cohort study', Neurology ISSN 0028-3878 (2022) [Refereed Article] DOI: 10.1212/WNL.0000000000201369 [eCite] [Details] Co-authors: Alty JE; Bindoff A; Stuart K; Hill E; Collins J; Vickers J Tweet
2022	Bartlett L, Doherty K, Farrow M, Kim S, Hill E, et al., 'Island Study Linking Aging and Neurodegenerative Disease (ISLAND) targeting dementia risk reduction: protocol for a prospective web-based cohort study', JMIR Research Protocols, 11, (3) Article e34688. ISSN 1929-0748 (2022) [Refereed Article] DOI: 10.2196/34688 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Bartlett L; Doherty K; Farrow M; Kim S; Hill E; Alty J; Eccleston C; Kitsos A; Bindoff A; Vickers JC Tweet
2022	Bramich S, King A, Kuruvilla M, Naismith SL, Noyce A, et al., 'Isolated REM sleep behaviour disorder: current diagnostic procedures and emerging new technologies', Journal of Neurology, 269, (9) pp. 4684-4695. ISSN 0340-5354 (2022) [Refereed Article] DOI: 10.1007/s00415-022-11213-9 [eCite] [Details] Co-authors: Bramich S; Kuruvilla M; Naismith SL; Alty J Tweet
2022	Chear S, Perry S, Wilson R, Bindoff A, Talbot J, et al., 'Lysosomal alterations and decreased electrophysiological activity in CLN3 disease patient-derived cortical neurons', Disease Models & Mechanisms, 15, (12) pp. 1-15. ISSN 1754-8403 (2022) [Refereed Article] DOI: 10.1242/dmm.049651 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 Co-authors: Chear S; Perry S; Wilson R; Bindoff A; Talbot J; Vickers JC; Hewitt AW; Cook AL Tweet
2022	Doust YV, Bindoff A, Holloway OG, Wilson R, King AE, et al., 'Temporal changes in the microglial proteome of male and female mice after a diffuse brain injury using label-free quantitative proteomics', Glia pp. 1-24. ISSN 0894-1491 (2022) [Refereed Article] DOI: 10.1002/glia.24313 [eCite] [Details] Co-authors: Doust YV; Bindoff A; Holloway OG; Wilson R; Ziebell JM Tweet
2021	Atkinson RAK, Fair HL, Wilson R, Vickers JC, King AE, 'Effects of TDP-43 overexpression on neuron proteome and morphology in vitro', Molecular and Cellular Neurosciences, 114 pp. 1-11. ISSN 1044-7431 (2021) [Refereed Article] DOI: 10.1016/j.mcn.2021.103627 [eCite] [Details] Co-authors: Atkinson RAK; Fair HL; Wilson R; Vickers JC Tweet
2021	Atkinson RAK, Leung J, Bender J, Kirkcaldie M, Vickers J, et al., 'TDP-43 mislocalization drives neurofilament changes in a novel model of TDP-43 proteinopathy', Disease Models & Mechanisms, 14, (2) pp. 1-14. ISSN 1754-8403 (2021) [Refereed Article] DOI: 10.1242/dmm.047548 [eCite] [Details] Citations: Scopus - 6Web of Science - 3 Co-authors: Atkinson RAK; Leung J; Bender J; Kirkcaldie M; Vickers J Tweet
2021	Bucher EA, Collins JM, King AE, Vickers JC, Kirkcaldie MTK, 'Coherence and cognition in the cortex: the fundamental role of parvalbumin, myelin, and the perineuronal net', Brain structure & Function, 226, (7) pp. 2041-2055. ISSN 1863-2653 (2021) [Refereed Article] DOI: 10.1007/s00429-021-02327-3 [eCite] [Details] Citations: Scopus - 5Web of Science - 6 Co-authors: Bucher EA; Collins JM; Vickers JC; Kirkcaldie MTK Tweet
2021	Collins JM, Hill E, Bindoff A, King AE, Alty J, et al., 'Association Between Components of Cognitive Reserve and Serum BDNF in Healthy Older Adults', Frontiers in Aging Neuroscience, 13 pp. 1-9. ISSN 1663-4365 (2021) [Refereed Article] DOI: 10.3389/fnagi.2021.725914 [eCite] [Details] Citations: Scopus - 6Web of Science - 6 Co-authors: Collins JM; Hill E; Bindoff A; Alty J; Summers MJ; Vickers JC Tweet
2021	Doust YV, King AE, Ziebell JM, 'Implications for microglial sex differences in tau-related neurodegenerative diseases', Neurobiology of Aging, 105 pp. 340-348. ISSN 0197-4580 (2021) [Refereed Article] DOI: 10.1016/j.neurobiolaging.2021.03.010 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Doust YV; Ziebell JM Tweet
2021	Khadka S, Khan S, King A, Goldberg LR, Crocombe L, et al., 'Poor oral hygiene, oral microorganisms and aspiration pneumonia risk in older people in residential aged care: a systematic review', Age and Ageing, 50, (1) pp. 81-87. ISSN 0002-0729 (2021) [Refereed Article] DOI: 10.1093/ageing/afaa102 [eCite] [Details] Citations: Scopus - 25Web of Science - 22 Co-authors: Khan S; Goldberg LR; Crocombe L; Bettiol SS Tweet
2021	Pan G, King A, Wu F, Simpson-Yap S, Woodhouse A, et al., 'The potential roles of genetic factors in predicting ageing-related cognitive change and Alzheimer's disease', Ageing Research Reviews, 70 pp. 1-15. ISSN 1568-1637 (2021) [Refereed Article] DOI: 10.1016/j.arr.2021.101402 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Pan G; Wu F; Simpson-Yap S; Woodhouse A; Vickers JC Tweet
2021	Stellon D, Nguyen Tran MP, Talbot J, Chear S, Mohd Khalid MKN, et al., 'CRISPR/Cas-Mediated Knock-in of genetically encoded fluorescent biosensors into the AAVS1 locus of human-induced pluripotent stem cells', Methods in Molecular Biology Article online ahead of print. ISSN 1064-3745 (2021) [Refereed Article] DOI: 10.1007/7651_2021_422 [eCite] [Details] Citations: Scopus - 2 Co-authors: Stellon D; Nguyen Tran MP; Talbot J; Chear S; Vickers JC; Hewitt AW; Cook AL Tweet
2021	Talbot J, Chear S, Phipps A, Pebay A, Hewitt AW, et al., 'Image-based quantitation of kainic acid-induced excitotoxicity as a model of neurodegeneration in Human iPSC-Derived Neurons', Methods in Molecular Biology ISSN 1064-3745 (2021) [Refereed Article] DOI: 10.1007/7651_2021_421 [eCite] [Details] Citations: Scopus - 1 Co-authors: Talbot J; Chear S; Phipps A; Hewitt AW; Vickers JC; Cook AL Tweet
2020	Collins JM, Woodhouse A, Bye N, Vickers JC, King AE, et al., 'Pathological links between traumatic brain injury and dementia: Australian pre-clinical research', Journal of Neurotrauma, 37, (5) pp. 782-791. ISSN 0897-7151 (2020) [Refereed Article] DOI: 10.1089/neu.2019.6906 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Collins JM; Woodhouse A; Bye N; Vickers JC; Ziebell JM Tweet
2020	Fulopova B, Stuart KE, Bennett W, Bindoff A, King AE, et al., 'Regional differences in beta amyloid plaque deposition and variable response to midlife environmental enrichment in the cortex of APP/PS1 mice', Journal of Comparative Neurology pp. 1-14. ISSN 0021-9967 (2020) [Refereed Article] DOI: 10.1002/cne.25060 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Co-authors: Fulopova B; Stuart KE; Bennett W; Bindoff A; Vickers JC; Canty AJ Tweet
2020	Holloway OG, King AE, Ziebell JM, 'Microglia demonstrate local mixed inflammation and a defined morphological shift in an APP/PS1 mouse model', Journal of Alzheimer's Disease, 77, (4) pp. 1765-1781. ISSN 1387-2877 (2020) [Refereed Article] DOI: 10.3233/JAD-200098 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Holloway OG; Ziebell JM Tweet
2020	Liu Y, Hanson KA, McCormack G, Atkinson RAK, Dittmann J, et al., 'Enhanced anti-amyloid effect of combined leptin and pioglitazone in app/ps1 transgenic mice', Current Alzheimer Research, 17, (14) pp. 1294-1301. ISSN 1567-2050 (2020) [Refereed Article] DOI: 10.2174/1567205018666210218163857 [eCite] [Details] Citations: Scopus - 4Web of Science - 5 Co-authors: Liu Y; McCormack G; Atkinson RAK; Dittmann J; Vickers JC Tweet
2020	Ooi L, Dottori M, Cook AL, Engel M, Gautam V, et al., 'If human brain organoids are the answer to understanding dementia, what are the questions?', The Neuroscientist, 26, (5-6) pp. 438-454. ISSN 1073-8584 (2020) [Refereed Article] DOI: 10.1177/1073858420912404 [eCite] [Details] Citations: Scopus - 18Web of Science - 14 Co-authors: Cook AL Tweet
2020	Ward DD, Summers MJ, Valenzuela MJ, Srikanth VK, Summers JJ, et al., 'Associations of later-life education, the BDNF Val66Met polymorphism and cognitive change in older adults', The Journal of Prevention of Alzheimer's Disease, 7, (1) pp. 37-42. ISSN 2274-5807 (2020) [Refereed Article] DOI: 10.14283/jpad.2019.40 [eCite] [Details] Citations: Scopus - 3Web of Science - 3 Co-authors: Ward DD; Summers MJ; Srikanth VK; Summers JJ; Robinson AL; Vickers JC Tweet
2019	Collins JM, King AE, Woodhouse A, Kirkcaldie MTK, Vickers JC, 'Age moderates the effects of traumatic brain injury on beta-amyloid plaque load in APP/PS1 mice', Journal of Neurotrauma, 36, (11) pp. 1876-1889. ISSN 0897-7151 (2019) [Refereed Article] DOI: 10.1089/neu.2018.5982 [eCite] [Details] Citations: Scopus - 12Web of Science - 12 Co-authors: Collins JM; Woodhouse A; Kirkcaldie MTK; Vickers JC Tweet
2019	Holloway OG, Canty AJ, King AE, Ziebell JM, 'Rod microglia and their role in neurological diseases', Seminars in Cell and Developmental Biology, 94 pp. 96-103. ISSN 1084-9521 (2019) [Refereed Article] DOI: 10.1016/j.semcdb.2019.02.005 [eCite] [Details] Citations: Scopus - 30Web of Science - 28 Co-authors: Holloway OG; Canty AJ; Ziebell JM Tweet
2019	Li F, Hung SSC, Mohd Khalid MKN, Wang J-H, Chrysostomou V, et al., 'Utility of self-destructing CRISPR/Cas constructs for targeted gene editing in the retina', Human Gene Therapy, 30, (11) pp. 1349-1360. ISSN 1043-0342 (2019) [Refereed Article] DOI: 10.1089/hum.2019.021 [eCite] [Details] Citations: Scopus - 15Web of Science - 15 Co-authors: Singh V; Wing K; Bender JA; Cook AL; Hewitt AW; Liu G-S Tweet
2019	Pietzuch M, King AE, Ward DD, Vickers JC, 'The influence of genetic factors and cognitive reserve on structural and functional resting-state brain networks in aging and Alzheimer's disease', Frontiers in Aging Neuroscience, 11 Article 30. ISSN 1663-4365 (2019) [Refereed Article] DOI: 10.3389/fnagi.2019.00030 [eCite] [Details] Citations: Scopus - 21Web of Science - 21 Co-authors: Pietzuch M; Vickers JC Tweet
2019	Stuart KE, King AE, King NE, Collins JM, Vickers JC, et al., 'Late-life environmental enrichment preserves short-term memory and may attenuate microglia in male APP/PS1 mice', Neuroscience, 408 pp. 282-292. ISSN 0306-4522 (2019) [Refereed Article] DOI: 10.1016/j.neuroscience.2019.04.015 [eCite] [Details] Citations: Scopus - 14Web of Science - 15 Co-authors: Stuart KE; King NE; Collins JM; Vickers JC; Ziebell JM Tweet
2019	Tian N, Hanson KA, Canty AJ, Vickers JC, King AE, 'Microtubule-dependent processes precede pathological calcium influx in excitotoxin-induced axon degeneration', Journal of Neurochemistry, 152, (5) pp. 542-555. ISSN 0022-3042 (2019) [Refereed Article] DOI: 10.1111/jnc.14909 [eCite] [Details] Citations: Scopus - 7Web of Science - 7 Co-authors: Tian N; Hanson KA; Canty AJ; Vickers JC Tweet
2019	Vickers JC, King AE, McCormack GH, Bindoff AD, Adlard PA, 'Iron is increased in the brains of ageing mice lacking the neurofilament light gene', PLoS ONE, 14, (10) Article e0224169. ISSN 1932-6203 (2019) [Refereed Article] DOI: 10.1371/journal.pone.0224169 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 Co-authors: Vickers JC; McCormack GH; Bindoff AD Tweet
2018	Chhetri J, King AE, Gueven N, 'Alzheimer's Disease and NQO1: is there a link?', Current Alzheimer Research, 15 pp. 56-66. ISSN 1567-2050 (2018) [Refereed Article] DOI: 10.2174/1567205014666170203095802 [eCite] [Details] Citations: Scopus - 30Web of Science - 25 Co-authors: Chhetri J; Gueven N Tweet
2018	Hanson K, Tian N, Vickers JC, King AE, 'The HDAC6 inhibitor trichostatin a acetylates microtubules and protects axons from excitotoxin-induced degeneration in a compartmented culture model', Frontiers in Neuroscience, 12, (NOV) Article 872. ISSN 1662-453X (2018) [Refereed Article] DOI: 10.3389/fnins.2018.00872 [eCite] [Details] Citations: Scopus - 10Web of Science - 8 Co-authors: Hanson K; Tian N; Vickers JC Tweet
2018	King A, Brain A, Hanson K, Dittmann J, Vickers J, et al., 'Disruption of leptin signalling in a mouse model of Alzheimer's disease', Metabolic Brain Disease, 33, (4) pp. 1097-1110. ISSN 0885-7490 (2018) [Refereed Article] DOI: 10.1007/s11011-018-0203-9 [eCite] [Details] Citations: Scopus - 17Web of Science - 18 Co-authors: Hanson K; Dittmann J; Vickers J; Fernandez-Martos C Tweet
2018	Leung JYK, Bennett WR, King AE, Chung RS, 'The impact of metallothionein-II on microglial response to tumor necrosis factor-alpha (TNFα) and downstream effects on neuronal regeneration', Journal of Neuroinflammation, 15, (1) pp. 1-9. ISSN 1742-2094 (2018) [Refereed Article] DOI: 10.1186/s12974-018-1070-3 [eCite] [Details] Citations: Scopus - 8Web of Science - 8 Co-authors: Leung JYK; Bennett WR; Chung RS Tweet
2018	O'Mara AR, Collins JM, King AE, Vickers JC, Kirkcaldie MTK, 'Accurate and unbiased quantitation of Amyloid-β fluorescence images using ImageSURF', Current Alzheimer Research, 16, (2) pp. 102-108. ISSN 1567-2050 (2018) [Refereed Article] DOI: 10.2174/1567205016666181212152622 [eCite] [Details] Citations: Scopus - 7Web of Science - 6 Co-authors: O'Mara AR; Collins JM; Vickers JC; Kirkcaldie MTK Tweet
2018	Tu L, Wang J-H, Barathi VA, Prea SM, He Z, et al., 'AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization', Angiogenesis, 21, (1) pp. 95-109. ISSN 0969-6970 (2018) [Refereed Article] DOI: 10.1007/s10456-017-9591-4 [eCite] [Details] Citations: Scopus - 15Web of Science - 15 Co-authors: Bender J; Liu G-S Tweet
2018	Woodhouse A, Fernandez-Martos CM, Atkinson RAK, Hanson KA, Collins JM, et al., 'Repeat propofol anesthesia does not exacerbate plaque deposition or synapse loss in APP/PS1 Alzheimer's disease mice', BMC Anesthesiology, 18, (1) Article 47. ISSN 1471-2253 (2018) [Refereed Article] DOI: 10.1186/s12871-018-0509-5 [eCite] [Details] Citations: Scopus - 6Web of Science - 6 Co-authors: Woodhouse A; Fernandez-Martos CM; Atkinson RAK; Hanson KA; Collins JM; O'Mara AR; Terblanche N; Skinner MW; Vickers JC Tweet
2017	Clark RM, Blizzard CA, Young KM, King AE, Dickson TC, 'Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1^G93A mouse model of ALS', Scientific Reports, 7 Article 44461. ISSN 2045-2322 (2017) [Refereed Article] DOI: 10.1038/srep44461 [eCite] [Details] Citations: Scopus - 26Web of Science - 25 Co-authors: Clark RM; Blizzard CA; Young KM; Dickson TC Tweet
2017	Cui H, King AE, Jacobson GA, Small DH, 'Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice', Journal of Neuroscience Research, 95, (4) pp. 992-999. ISSN 0360-4012 (2017) [Refereed Article] DOI: 10.1002/jnr.23880 [eCite] [Details] Citations: Scopus - 5Web of Science - 3 Co-authors: Cui H; Jacobson GA; Small DH Tweet
2017	Imlach A, Ward DD, Stuart KE, Summers MJ, Valenzuela MJ, et al., 'Age is no barrier: predictors of academic success in older learners', npj Science of Learning, 2 Article 13. ISSN 2056-7936 (2017) [Refereed Article] DOI: 10.1038/s41539-017-0014-5 [eCite] [Details] Citations: Scopus - 13Web of Science - 14 Co-authors: Imlach A; Ward DD; Stuart KE; Summers MJ; Saunders NL; Summers J; Srikanth VK; Robinson A; Vickers JC Tweet
2017	O'Mara A, King AE, Vickers JC, Kirkcaldie MTK, 'ImageSURF: An ImageJ plugin for batch pixel-based image segmentation using random forests', Journal of Open Research Software, 5 Article 31. ISSN 2049-9647 (2017) [Refereed Article] DOI: 10.5334/jors.172 [eCite] [Details] Co-authors: O'Mara A; Vickers JC; Kirkcaldie MTK Tweet
2017	Stuart KE, King AE, Fernandez-Martos CM, Dittmann J, Summers MJ, et al., 'Mid-life environmental enrichment increases synaptic density in CA1 in a mouse model of Aβ-associated pathology and positively influences synaptic and cognitive health in healthy ageing', Journal of Comparative Neurology, 525, (8) pp. 1797-1810. ISSN 0021-9967 (2017) [Refereed Article] DOI: 10.1002/cne.24156 [eCite] [Details] Citations: Scopus - 28Web of Science - 27 Co-authors: Stuart KE; Fernandez-Martos CM; Dittmann J; Summers MJ; Vickers JC Tweet
2017	Stuart KE, King AE, Fernandez-Martos CM, Summers MJ, Vickers JC, 'Environmental novelty exacerbates stress hormones and Aβ pathology in an Alzheimer's model', Scientific Reports, 7, (1) Article 2764. ISSN 2045-2322 (2017) [Refereed Article] DOI: 10.1038/s41598-017-03016-0 [eCite] [Details] Citations: Scopus - 15Web of Science - 11 Co-authors: Stuart KE; Fernandez-Martos CM; Summers MJ; Vickers JC Tweet
2017	Yap YC, King AE, Guijt RM, Jiang T, Blizzard CA, et al., 'Mild and repetitive very mild axonal stretch injury triggers cystoskeletal mislocalization and growth cone collapse', PLoS One, 12, (5) Article e0176997. ISSN 1932-6203 (2017) [Refereed Article] DOI: 10.1371/journal.pone.0176997 [eCite] [Details] Citations: Scopus - 24Web of Science - 21 Co-authors: Yap YC; Guijt RM; Blizzard CA; Breadmore MC; Dickson TC Tweet
2016	Clark JA, Southam KA, Blizzard CA, King AE, Dickson TC, 'Axonal degeneration, distal collateral branching and neuromuscular junction architecture alterations occur prior to symptom onset in the SOD1^G93A mouse model of amyotrophic lateral sclerosis', Journal of Chemical Neuroanatomy, 76, (Pt A) pp. 35-47. ISSN 0891-0618 (2016) [Refereed Article] DOI: 10.1016/j.jchemneu.2016.03.003 [eCite] [Details] Citations: Scopus - 57Web of Science - 55 Co-authors: Clark JA; Southam KA; Blizzard CA; Dickson TC Tweet
2016	Fernandez-Martos CM, Atkinson RAK, Chuah MI, King AE, Vickers JC, 'Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer's disease', Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3, (1) pp. 92-106. ISSN 2352-8737 (2016) [Refereed Article] DOI: 10.1016/j.trci.2016.11.002 [eCite] [Details] Citations: Scopus - 30 Co-authors: Fernandez-Martos CM; Atkinson RAK; Chuah MI; Vickers JC Tweet
2016	Gupta VK, Chitranshi N, Gupta VB, Golzan M, Dheer Y, et al., 'Amyloid β accumulation and inner retinal degenerative changes in Alzheimer's disease transgenic mouse', Neuroscience Letters, 623 pp. 52-56. ISSN 0304-3940 (2016) [Refereed Article] DOI: 10.1016/j.neulet.2016.04.059 [eCite] [Details] Citations: Scopus - 80Web of Science - 81 Co-authors: Vickers JC Tweet
2016	Hung SSC, Chrysostomou V, Li F, Lim JKH, Wang J-H, et al., 'AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo', Investigative Ophthalmology & Visual Science, 57, (7) pp. 3470-3476. ISSN 1552-5783 (2016) [Refereed Article] DOI: 10.1167/iovs.16-19316 [eCite] [Details] Citations: Scopus - 94Web of Science - 87 Co-authors: Liu G-S; Hewitt AW Tweet
2016	King AE, Woodhouse A, Kirkcaldie MTK, Vickers JC, 'Excitotoxicity in ALS: Overstimulation, or overreaction?', Experimental Neurology, 275 pp. 162-171. ISSN 0014-4886 (2016) [Refereed Article] DOI: 10.1016/j.expneurol.2015.09.019 [eCite] [Details] Citations: Scopus - 106Web of Science - 107 Co-authors: Woodhouse A; Kirkcaldie MTK; Vickers JC Tweet
2016	Vickers J, Mitew S, Woodhouse A, Fernandez-Martos CM, Kirkcaldie MT, et al., 'Defining the earliest pathological changes of Alzheimer's disease', Current Alzheimer research, 13, (3) pp. 281-287. ISSN 1567-2050 (2016) [Refereed Article] DOI: 10.2174/1567205013666151218150322 [eCite] [Details] Citations: Scopus - 64Web of Science - 58 Co-authors: Vickers J; Mitew S; Woodhouse A; Fernandez-Martos CM; Kirkcaldie MT; Canty AJ; McCormack GH Tweet
2016	Vickers JC, Kirkcaldie MT, Phipps A, King AE, 'Alterations in neurofilaments and the transformation of the cytoskeleton in axons may provide insight into the aberrant neuronal changes of Alzheimer's disease', Brain Research Bulletin, 126, (Pt 3) pp. 324-333. ISSN 0361-9230 (2016) [Refereed Article] DOI: 10.1016/j.brainresbull.2016.07.012 [eCite] [Details] Citations: Scopus - 11Web of Science - 12 Co-authors: Vickers JC; Kirkcaldie MT; Phipps A Tweet
2015	Atkinson RA, Fernandez-Martos CM, Atkin J, Vickers JC, King AE, 'C9ORF72 expression and cellular localization over mouse development', Acta neuropathologica communications, 3 Article 59. ISSN 2051-5960 (2015) [Refereed Article] DOI: 10.1186/s40478-015-0238-7 [eCite] [Details] Citations: Scopus - 22Web of Science - 27 Co-authors: Atkinson RA; Fernandez-Martos CM; Vickers JC Tweet
2015	Blizzard CA, Southam KA, Dawkins E, Lewis KE, King AE, et al., 'Identifying the primary site of pathogenesis in amyotrophic lateral sclerosis - vulnerability of lower motor neurons to proximal excitotoxicity', Disease Models & Mechanisms, 8, (3) pp. 215-224. ISSN 1754-8403 (2015) [Refereed Article] DOI: 10.1242/dmm.018606 [eCite] [Details] Citations: Scopus - 30Web of Science - 31 Co-authors: Blizzard CA; Southam KA; Dawkins E; Lewis KE; Clark JA; Dickson TC Tweet
2015	Collins JM, King AE, Woodhouse A, Kirkcaldie MTK, Vickers JC, 'The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease', Experimental Neurology, 267 pp. 219-29. ISSN 0014-4886 (2015) [Refereed Article] DOI: 10.1016/j.expneurol.2015.02.034 [eCite] [Details] Citations: Scopus - 39Web of Science - 39 Co-authors: Collins JM; Woodhouse A; Kirkcaldie MTK; Vickers JC Tweet
2015	Fernandez-Martos CM, King AE, Atkinson RAK, Woodhouse A, Vickers JC, 'Neurofilament light gene deletion exacerbates amyloid, dystrophic neurite, and synaptic pathology in the APP/PS1 transgenic model of Alzheimer's disease', Neurobiology of Aging, 36, (10) pp. 2757-2767. ISSN 0197-4580 (2015) [Refereed Article] DOI: 10.1016/j.neurobiolaging.2015.07.003 [eCite] [Details] Citations: Scopus - 22Web of Science - 20 Co-authors: Fernandez-Martos CM; Atkinson RAK; Woodhouse A; Vickers JC Tweet
2015	Franks K, Chuah MI, King AE, Vickers JC, 'Connectivity of pathology: the olfactory system as a model for network-driven mechanisms of Alzheimer's disease pathogenesis', Frontiers in Aging Neuroscience, 7 Article 234. ISSN 1663-4365 (2015) [Refereed Article] DOI: 10.3389/fnagi.2015.00234 [eCite] [Details] Citations: Scopus - 29Web of Science - 28 Co-authors: Franks K; Chuah MI; Vickers JC Tweet
2015	Liu Y, Atkinson RAK, Fernandez-Martos CM, Kirkcaldie MTK, Cui H, et al., 'Changes in TDP-43 expression in development, aging, and in the neurofilament light protein knockout mouse', Neurobiology of Aging: Experimental and Clinical Research, 36, (2) pp. 1151-1159. ISSN 0197-4580 (2015) [Refereed Article] DOI: 10.1016/j.neurobiolaging.2014.10.001 [eCite] [Details] Citations: Scopus - 11Web of Science - 10 Co-authors: Liu Y; Atkinson RAK; Fernandez-Martos CM; Kirkcaldie MTK; Vickers JC Tweet
2015	Soo KY, Halloran M, Sundaramoorthy V, Parakh S, Toth RP, et al., 'Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS', Acta Neuropathologica, 130, (5) pp. 679-697. ISSN 0001-6322 (2015) [Refereed Article] DOI: 10.1007/s00401-015-1468-2 [eCite] [Details] Citations: Scopus - 74Web of Science - 73 Co-authors: Southam KA Tweet
2015	Soo KY, Sultana J, King AE, Atkinson RAK, Warraich ST, et al., 'ALS-associated mutant FUS inhibits macroautophagy which is restored by overexpression of Rab1', Cell Death Discovery, 1 Article 15030. ISSN 2058-7716 (2015) [Refereed Article] DOI: 10.1038/cddiscovery.2015.30 [eCite] [Details] Citations: Scopus - 43Web of Science - 44 Co-authors: Atkinson RAK Tweet
2014	Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RAK, et al., 'C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking', Human Molecular Genetics, 23, (13) Article ddu068. ISSN 0964-6906 (2014) [Refereed Article] DOI: 10.1093/hmg/ddu068 [eCite] [Details] Citations: Scopus - 320Web of Science - 305 Co-authors: Atkinson RAK Tweet
2014	Lewis KE, Rasmussen A, Bennett W, King A, West AK, et al., 'Microglia and motor neurons during disease progression in the SOD1^G93A mouse model of amyotrophic lateral sclerosis: Changes in arginase1 and inducible nitric oxide synthase', Journal of Neuroinflammation, 11 Article 55. ISSN 1742-2094 (2014) [Refereed Article] DOI: 10.1186/1742-2094-11-55 [eCite] [Details] Citations: Scopus - 48Web of Science - 51 Co-authors: Lewis KE; Rasmussen A; Bennett W; West AK; Chung RS; Chuah MI Tweet
2014	Musgrove RE, Horne H, Wilson R, King AE, Edwards LM, et al., 'The metabolomics of alpha-synuclein (SNCA) gene deletion and mutation in mouse brain', Metabolomics, 10, (1) pp. 114-122. ISSN 1573-3882 (2014) [Refereed Article] DOI: 10.1007/s11306-013-0561-6 [eCite] [Details] Citations: Scopus - 11Web of Science - 10 Co-authors: Musgrove RE; Horne H; Wilson R; Edwards LM; Dickson TC Tweet
2014	Siedler DG, Chuah MI, Kirkcaldie MTK, Vickers JC, King AE, 'Diffuse axonal injury in brain trauma: insights from alterations in neurofilaments', Frontiers in Cellular Neuroscience, 8 Article 429. ISSN 1662-5102 (2014) [Refereed Article] DOI: 10.3389/fncel.2014.00429 [eCite] [Details] Citations: Scopus - 78Web of Science - 70 Co-authors: Siedler DG; Chuah MI; Kirkcaldie MTK; Vickers JC Tweet
2014	Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM, 'Microfluidic culture platform for studying neuronal response to mild to very mild axonal stretch injury', Biomicrofluidics, 8, (4) Article 044110. ISSN 1932-1058 (2014) [Refereed Article] DOI: 10.1063/1.4891098 [eCite] [Details] Citations: Scopus - 25Web of Science - 21 Co-authors: Yap YC; Dickson TC; Breadmore MC; Guijt RM Tweet
2013	Blizzard CA, King AE, Vickers J, Dickson T, 'Cortical murine neurons lacking the neurofilament light chain protein have an attenuated response to injury in vitro', Journal of Neurotrauma, 30, (22) pp. 1908-1918. ISSN 0897-7151 (2013) [Refereed Article] DOI: 10.1089/neu.2013.2850 [eCite] [Details] Citations: Scopus - 9Web of Science - 8 Co-authors: Blizzard CA; Vickers J; Dickson T Tweet
2013	King AE, Southam KA, Dittmann J, Vickers JC, 'Excitotoxin-induced caspase-3 activation and microtubule disintegration in axons is inhibited by taxol', Acta Neuropathologica Communications, 1 Article 59. ISSN 2051-5960 (2013) [Refereed Article] DOI: 10.1186/2051-5960-1-59 [eCite] [Details] Citations: Scopus - 20Web of Science - 20 Co-authors: Southam KA; Dittmann J; Vickers JC Tweet
2013	Musgrove RE, King AE, Dickson TC, 'α-Synuclein protects neurons from apoptosis downstream of free-radical production through modulation of the MAPK signalling pathway', Neurotoxicity Research, 23, (4) pp. 358-369. ISSN 1476-3524 (2013) [Refereed Article] DOI: 10.1007/s12640-012-9352-5 [eCite] [Details] Citations: Scopus - 26Web of Science - 25 Co-authors: Musgrove RE; Dickson TC Tweet
2013	Southam KA, King AE, Blizzard CA, McCormack GH, Dickson TC, 'Microfluidic primary culture model of the lower motor neuron-neuromuscular junction circuit', Journal of Neuroscience Methods, 218, (2) pp. 164-169. ISSN 0165-0270 (2013) [Refereed Article] DOI: 10.1016/j.jneumeth.2013.06.002 [eCite] [Details] Citations: Scopus - 81Web of Science - 76 Co-authors: Southam KA; Blizzard CA; McCormack GH; Dickson TC Tweet
2013	Yap YC, Guijt RM, Dickson TC, King AE, Breadmore MC, 'Stainless steel pinholes for fast fabrication of high-performance microchip electrophoresis devices by CO₂ laser ablation', Analytical Chemistry, 85, (21) pp. 10051-10056. ISSN 0003-2700 (2013) [Refereed Article] DOI: 10.1021/ac402631g [eCite] [Details] Citations: Scopus - 17Web of Science - 14 Co-authors: Yap YC; Guijt RM; Dickson TC; Breadmore MC Tweet
2012	Hosie KA, King AE, Blizzard CA, Vickers JC, Dickson TC, 'Chronic excitotoxin-induced axon degeneration in a compartmented neuronal culture model', ASN Neuro, 4, (1) Article e00076. ISSN 1759-0914 (2012) [Refereed Article] DOI: 10.1042/AN20110031 [eCite] [Details] Citations: Scopus - 42Web of Science - 38 Co-authors: Hosie KA; Blizzard CA; Vickers JC; Dickson TC Tweet
2012	King AE, Blizzard CA, Southam KA, Vickers JC, Dickson TC, 'Degeneration of axons in spinal white matter in G93A mSOD1 mouse characterized by NFL and alpha internexin immunoreactivity', Brain Research, 1465 pp. 90-100. ISSN 0006-8993 (2012) [Refereed Article] DOI: 10.1016/j.brainres.2012.05.018 [eCite] [Details] Citations: Scopus - 18Web of Science - 14 Co-authors: Blizzard CA; Southam KA; Vickers JC; Dickson TC Tweet
2012	Liu Yao, Staal JA, Canty AJ, Kirkcaldie MTK, King AE, et al., 'Cytoskeletal changes during development and aging in the cortex of neurofilament light protein knockout mice', The Journal of Comparative Neurology, 521, (8) pp. 1817-1827. ISSN 0021-9967 (2012) [Refereed Article] DOI: 10.1002/cne.23261 [eCite] [Details] Citations: Scopus - 14Web of Science - 14 Co-authors: Liu Yao; Staal JA; Canty AJ; Kirkcaldie MTK; Bibari O; Mitew ST; Dickson TC; Vickers JC Tweet
2011	Blizzard CA, Chuckowree JA, King AE, Hosie KA, McCormack GH, et al., 'Focal Damage to the Adult Rat Neocortex Induces Wound Healing Accompanied by Axonal Sprouting and Dendritic Structural Plasticity ', Cerebral Cortex, 21, (2) pp. 281-291. ISSN 1047-3211 (2011) [Refereed Article] DOI: 10.1093/cercor/bhq091 [eCite] [Details] Citations: Scopus - 31Web of Science - 32 Co-authors: Blizzard CA; Chuckowree JA; Hosie KA; McCormack GH; Chapman JA; Vickers JC; Dickson TC Tweet
2011	King AE, Dickson TC, Blizzard CA, Woodhouse A, Foster SS, et al., 'Neuron-glia interactions underlie ALS-like axonal cytoskeletal pathology', Neurobiology of Aging: Experimental and Clinical Research, 32, (3) pp. 459-469. ISSN 0197-4580 (2011) [Refereed Article] DOI: 10.1016/j.neurobiolaging.2009.04.004 [eCite] [Details] Citations: Scopus - 27Web of Science - 25 Co-authors: Dickson TC; Blizzard CA; Woodhouse A; Foster SS; Chung RS; Vickers JC Tweet
2011	Musgrove RE, King AE, Dickson TC, 'Neuroprotective upregulation of endogenous alpha-synuclein precedes ubiquitination in cultured dopaminergic neurons ', Neurotoxicity Research , 19, (4) pp. 592-602. ISSN 1029-8428 (2011) [Refereed Article] DOI: 10.1007/s12640-010-9207-x [eCite] [Details] Citations: Scopus - 15Web of Science - 13 Co-authors: Musgrove RE; Dickson TC Tweet
2009	Blizzard CA, King AE, Haas MA, O'Toole DA, Vickers JC, et al., 'Axonal shearing in mature cortical neurons induces attempted regeneration and the reestablishment of neurite polarity', Brain Research: International Multidisciplinary Journal Devoted to Fundamental Research in The Brain Sciences, 1300, (November) pp. 24-36. ISSN 0006-8993 (2009) [Refereed Article] DOI: 10.1016/j.brainres.2009.08.059 [eCite] [Details] Citations: Scopus - 2Web of Science - 3 Co-authors: Blizzard CA; Haas MA; O'Toole DA; Vickers JC; Dickson TC Tweet
2009	Vickers JC, King AE, Woodhouse A, Kirkcaldie MT, Staal JA, et al., 'Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system ', Brain Research Bulletin, 80, (4-5) pp. 217-223. ISSN 0361-9230 (2009) [Refereed Article] DOI: 10.1016/j.brainresbull.2009.08.004 [eCite] [Details] Citations: Scopus - 56Web of Science - 54 Co-authors: Vickers JC; Woodhouse A; Kirkcaldie MT; Staal JA; McCormack GH; Blizzard CA; Musgrove RE; Mitew S; Liu Y; Chuckowree JA; Bibari O; Dickson TC Tweet
2009	Woodhouse A, Shepherd CE, Sokolova A, Carroll V, King AE, et al., 'Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease', Acta Neuropathologica, 117, (1) pp. 19-29. ISSN 0001-6322 (2009) [Refereed Article] DOI: 10.1007/s00401-008-0458-z [eCite] [Details] Citations: Scopus - 23Web of Science - 21 Co-authors: Woodhouse A; Sokolova A; Carroll V; Dickson TC; Vickers JC Tweet
2007	King AE, Dickson TC, Blizzard CA, Foster SS, Chung RS, et al., 'Excitotoxicity mediated by non-NMDA receptors causes distal axonopathy in long-term cultured spinal motor neurons', European Journal of Neuroscience, 26, (8) pp. 2151-2159. ISSN 0953-816X (2007) [Refereed Article] DOI: 10.1111/j.1460-9568.2007.05845.x [eCite] [Details] Citations: Scopus - 32Web of Science - 26 Co-authors: Dickson TC; Blizzard CA; Foster SS; Chung RS; West AK; Chuah MI; Vickers JC Tweet
2006	King AE, Bartlett C, Sauve Y, Lund R, Dunlop S, et al., 'Retinal ganglion cell axons regenerate in the presence of intact sensory fibres', Neuroreport, 17, (2) pp. 195-199. ISSN 0959-4965 (2006) [Refereed Article] DOI: 10.1097/01.wnr.0000195668.07467.a8 [eCite] [Details] Citations: Scopus - 2Web of Science - 2 Tweet
2006	King AE, Chung RS, Vickers JC, Dickson TC, 'Localisation of glutamate receptors in developing cortical neurons in culture and relationship to susceptibility to excitotoxicity', Journal of Comparative Neurology, 498, (2) pp. 277-294. ISSN 0021-9967 (2006) [Refereed Article] DOI: 10.1002/cne.21053 [eCite] [Details] Citations: Scopus - 42Web of Science - 41 Co-authors: Chung RS; Vickers JC; Dickson TC Tweet
2006	Quilty MC, King AE, Gai WP, Pountney DL, West AK, et al., 'Alpha-synuclein is upregulated in neurones in response to chronic oxidative stress and is associated with neuroprotection', Experimental Neurology, 199, (2) pp. 249-256. ISSN 0014-4886 (2006) [Refereed Article] DOI: 10.1016/j.expneurol.2005.10.018 [eCite] [Details] Citations: Scopus - 88Web of Science - 78 Co-authors: Quilty MC; Gai WP; West AK; Vickers JC; Dickson TC Tweet
2005	Chung RS, McCormack GH, King AE, West AK, Vickers JC, 'Glutamate induces rapid loss of axonal neurofilament proteins from cortical neurons in vitro', Experimental Neurology, 193, (2) pp. 481-488. ISSN 0014-4886 (2005) [Refereed Article] DOI: 10.1016/j.expneurol.2005.01.005 [eCite] [Details] Citations: Scopus - 37Web of Science - 35 Co-authors: Chung RS; McCormack GH; West AK; Vickers JC Tweet

Chapter in Book

(4 outputs)

Year	Citation	Altmetrics
2018	Hung SS, Li F, Wang J-H, King AE, Bui BV, et al., 'Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina', Retinal Gene Therapy: Methods and Protocols, Humana Press, CJF Boon, J Wijnholds (ed), United States, pp. 113-133. ISBN 978-1-4939-7521-1 (2018) [Other Book Chapter] DOI: 10.1007/978-1-4939-7522-8_9 [eCite] [Details] Citations: Scopus - 7 Co-authors: Liu G Tweet
2017	Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM, 'Microfluidic Device for Studying Traumatic Brain Injury', Stem Cell Technologies in Neuroscience, Springer Science+Business Media LLC, AK Srivastava, EY Snyder, YD Teng (ed), New York, United States, pp. 145-156. ISBN 9781493970223 (2017) [Research Book Chapter] DOI: 10.1007/978-1-4939-7024-7_10 [eCite] [Details] Citations: Scopus - 4 Co-authors: Yap YC; Dickson TC; Breadmore MC; Guijt RM Tweet
2015	Southam KA, King AE, Blizzard CA, McCormack GH, Dickson T, 'A Novel In Vitro Primary Culture Model of the Lower Motor Neuron-Neuromuscular Junction Circuit', Microfluidic and Compartmentalized Platforms for Neurobiological Research, Springer, E Biffi (ed), United States, pp. 181-193. ISBN 978-1-4939-2509-4 (2015) [Other Book Chapter] DOI: 10.1007/978-1-4939-2510-0_11 [eCite] [Details] Citations: Scopus - 1 Co-authors: Southam KA; Blizzard CA; McCormack GH; Dickson T Tweet
2014	King AE, Vickers JC, 'Excitotoxicity and Axon Degeneration', Handbook of Neurotoxicity, Springer, R Kostrzewa (ed), New York, pp. 1223-1245. ISBN 978-1-4614-5835-7 (2014) [Other Book Chapter] DOI: 10.1007/978-1-4614-5836-4_145 [eCite] [Details] Citations: Scopus - 1 Co-authors: Vickers JC Tweet

Conference Publication

(59 outputs)

Year	Citation	Altmetrics
2022	Alty J, Salmon K, Lawler K, McDonald S, Stuart K, et al., 'The ISLAND clinic: first year outcomes of a new state-wide one-stop' cognitive clinic in Tasmania', ADRF - Australian Dementia Research Forum, 30-31 May 2022, Online (2022) [Conference Extract] [eCite] [Details] Co-authors: Alty J; Salmon K; Lawler K; McDonald S; Stuart K; Cleary A; Beaumont M; Radfar N; Collins J; Ma WJ; Vickers J Tweet
2021	Alty J, Bai Q, St George RJ, Bindoff A, Li R, et al., 'TasTest: moving towards a digital screening test for pre-clinical Alzheimer's disease', Biomarkers ISSN 1354-750X (2021) [Conference Extract] DOI: 10.1002/alz.058732 [eCite] [Details] Co-authors: Alty J; Bai Q; St George RJ; Bindoff A; Li R; Lawler K; Hill E; Garg G; Bartlett L; Vickers JC Tweet
2021	Goldberg L, Crocombe L, Bettiol S, King A, Khadka S, 'Reducing aspiration pneumonia risk for older people: effect of evidence-based oral care', GSA 2021 Annual Scientific Meeting, 10-13 November 2021, Virtual Conference, Online (2021) [Conference Extract] [eCite] [Details] Co-authors: Goldberg L; Crocombe L; Bettiol S
2021	Hill E, Collins J, Bindoff A, King A, Alty J, et al., 'Increased age and higher levels of cognitive reserve are associated with lower serum BDNF levels in healthy older adults', Australian Dementia Forum 2021, 31 May - 1 June, virtual (2021) [Conference Extract] [eCite] [Details] Co-authors: Hill E; Collins J; Bindoff A; Alty J; Summers M; Vickers J
2020	Bartlett L, Doherty K, Farrow M, Bindoff A, Kim S, et al., 'Poster - The island study linking ageing and neurodegenerative disease (ISLAND): a longitudinal public health research program targeting dementia risk reduction', 2020 Alzheimer's Association International Conference, 26-30 July 2020, Online (2020) [Conference Extract] [eCite] [Details] Co-authors: Bartlett L; Doherty K; Farrow M; Bindoff A; Kim S; Eccleston C; Hill E; Alty J; Vickers JC Tweet
2020	Bartlett L, Doherty K, Farrow M, Bindoff A, Kim S, et al., 'The Island Study Linking Ageing and Neurodegenerative Disease (ISLAND): A longitudinal public health research program targeting dementia risk reduction', Alzheimer's & Dementia ISSN 1552-5260 (2020) [Conference Extract] DOI: 10.1002/alz.045539 [eCite] [Details] Co-authors: Bartlett L; Doherty K; Farrow M; Bindoff A; Kim S; Eccleston C; Hill E; Alty JE; Vickers JC Tweet
2020	Bucher E, McManus J, King A, Vickers J, Kirkcaldie M, 'Whisker trimming, when combined with sleep disruption, reduces the quantity of amyloid-β pathology in an Alzheimer's disease mouse model', Federation of European Neuroscience Society (FENS) Forum, 11-15 July, Online (2020) [Conference Extract] [eCite] [Details] Co-authors: Bucher E; McManus J; Vickers J; Kirkcaldie M
2019	Bucher E, McManus J, King A, Vickers J, Kirkcaldie M, 'Poster 5.5 - Induced neuroplasticity, when combined with sleep disruption, reduces the quantity of amyloid-β pathology in an Alzheimer's disease mouse model', Australia Dementia Forum 2019 - Shining a light on the impact of dementia research, 13-14 June 2019, Hobart, Tasmania (2019) [Conference Extract] [eCite] [Details] Co-authors: Bucher E; McManus J; Vickers J; Kirkcaldie M
2019	Goldberg L, Crocombe L, Breen J, King A, 'Harnessing the power of evidence to inform policy, improve oral health, and decrease aspiration pneumonia risk for people with dementia in residential aged care', NHMRC Conference on Research Translation, November 19-20, Melbourne, Victoria (2019) [Conference Extract] [eCite] [Details] Co-authors: Goldberg L; Crocombe L; Breen J
2019	Goldberg L, Crocombe L, Breen J, King A, 'Harnessing the power of evidence to improve oral health, decrease aspiration pneumonia risk and impact policy for people with dementia in residential aged care', 12th Annual Conference on the Science of Dissemination and Implementation in Health, December 4-6, Arlington, Virginia, USA (2019) [Conference Extract] [eCite] [Details] Co-authors: Goldberg L; Crocombe L; Breen J
2019	Goldberg LR, Crocombe L, Breen J, Bettiol SS, King AE, et al., 'Working interprofessionally to improve oral health and reduce aspiration pneumonia risk', 15th National Rural Health Conference, 24-27 March 2019, Hobart, Tasmania (2019) [Conference Extract] [eCite] [Details] Co-authors: Goldberg LR; Crocombe L; Bettiol SS; Kent K; Lea EJ; McInerney F
2019	Khadka S, Bettiol S, Goldberg LR, King A, McCammon S, et al., 'Effect of a six-week period of evidence-based daily oral care on the oral microbiome of people with dementia living in residential aged care', Federation of European Microbiological Society Meeting - Microbiome, 18-21 July, New York, United States (2019) [Conference Extract] [eCite] [Details] Co-authors: Bettiol S; Goldberg LR; McCammon S; Crocombe L Tweet
2019	Kirkcaldie M, O'Mara A, King A, Vickers J, 'Making the most of Alzheimer's models: accurate measurement of amyloid from microscope images using ImageSURF', Australian Dementia Forum, 13-14 June, Hobart, Tasmania (2019) [Conference Extract] [eCite] [Details] Co-authors: Kirkcaldie M; O'Mara A; Vickers J
2019	McManus J, Bucher E, King A, Vickers J, Kirkcaldie M, 'Examining gene expression following sleep disruption and induced plasticity in Alzheimer's model mice', Australian Dementia Forum 2019 - Shinning a light on the impact of dementia research, 13-14 June, Hobart, Tasmania (2019) [Conference Extract] [eCite] [Details] Co-authors: McManus J; Bucher E; Vickers J; Kirkcaldie M
2018	Dwyer S, Leung JYK, Kirkcaldie M, Vickers JC, King AE, '743.10 / P4 - Oligodendrocyte and myelin alterations in Alzheimer's disease', Neuroscience 2018, 3-7 November, San Diego, CA (2018) [Conference Extract] [eCite] [Details] Co-authors: Dwyer S; Leung JYK; Kirkcaldie M; Vickers JC Tweet
2018	Khadka S, Bettiol S, King A, Goldberg LR, McCammon SA, et al., 'Comparison of DNA extraction and quantification methods to estimate bacterial load in oral cavity', Molecular Microbiology Meeting 2018, 11-12 April 2018, Sydney (2018) [Conference Extract] [eCite] [Details] Co-authors: Bettiol S; Goldberg LR; McCammon SA; Crocombe LA
2018	Kirkcaldie M, Bucher E, McManus J, King A, Vickers J, '046.08 / O6 - Neither sleep disruption nor induced cortical plasticity precipitates the onset of amyloid-β pathology in an Alzheimer's disease mouse model: preliminary data from a study of sleep and plasticity as risk factors', Neuroscience 2018, 3-7 November, San Diego, CA (2018) [Conference Extract] [eCite] [Details] Co-authors: Kirkcaldie M; Bucher E; McManus J; Vickers J Tweet
2018	McManus J, Bucher E, King A, Vickers J, Kirkcaldie M, 'Effects of sleep disruption and induced cortical plasticity on early amyloid-β accumulation and gene expression in a mouse model of Alzheimer's disease', Australasian Neuroscience Societies' 38th Annual Scientific Meeting, Brisbane, Australia (2018) [Conference Extract] [eCite] [Details] Co-authors: McManus J; Bucher E; Vickers J; Kirkcaldie M
2017	Goldberg LR, Canty A, King AE, Price AD, Carr AR, et al., 'Can mature -age non-traditional students succeed in an online Bachelor of Dementia Care program?', International Association of Gerontology and Geriatrics (IAGG) World Congress, San Francisco, 23-27 July 2017, San Francisco (2017) [Conference Extract] [eCite] [Details] Co-authors: Goldberg LR; Canty A; Price AD; Carr AR; Ziebell JM; Westbury JL; Elliot K-E
2017	Khadka S, Bettiol SS, Goldberg LR, King AE, Crocombe LA, 'Identification of type and load of oral microorganisms associated with ill health and aspiration pneumonia in people living in residential aged care', Tasmania Health Conference 2017, Hobart, Tasmania (2017) [Conference Extract] [eCite] [Details] Co-authors: Bettiol SS; Goldberg LR; Crocombe LA
2016	Dwyer ST, Leung JYK, Kirkcaldie M, Vickers J, King A, 'Poster 107 - Modelling the effect of Amyloid Beta in oligodendrocyte differentiation and maturation', Australasian Neuroscience Society Annual Scientific Meeting 2016, 4-7 December, Hobart, Tasmania (2016) [Conference Extract] [eCite] [Details] Co-authors: Dwyer ST; Leung JYK; Kirkcaldie M; Vickers J
2016	O'Mara AR, King AE, Vickers JC, Kirkcaldie MTK, 'Poster 286 - ImageSURF: an ImageJ plugin for accurate and unbiased segmentation of fluorescent images', Austalasian Neuroscience Society Annual Scientific Meeting 2016, 4-7 December, Hobart, Tasmania (2016) [Conference Extract] [eCite] [Details] Co-authors: O'Mara AR; Vickers JC; Kirkcaldie MTK
2015	Yap YC, Dickson TC, King AE, Guijt RM, Breadmore MC, 'Microfluidic maze for studying the role of neuron-glia signalling in neuronal networks', Proceedings of the 19th International Conference on Miniaturized Systems for Chemistry and Life Sciences (MicroTAS 2015), 25-29 October, Gyeongju, South Korea, pp. 648-650. ISBN 978-097980648-3 (2015) [Conference Extract] [eCite] [Details] Co-authors: Yap YC; Dickson TC; Guijt RM; Breadmore MC Tweet
2014	Collins J, King A, Woodhouse A, Kirkcaldie M, Vickers J, 'The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease', Society for Neuroscience Meeting 2014, November 2014, Washington DC (2014) [Conference Extract] [eCite] [Details] Co-authors: Collins J; Woodhouse A; Kirkcaldie M; Vickers J
2014	King AE, Fernandez-Martos CM, Hanson K, Woodhouse A, Vickers JC, 'The role of anesthesia in exacerbation of ad pathology in a transgenic mouse model of amyloid plaque deposition', Australian Neuroscience Society Conference, 28-31 January 2014, Adelaide (2014) [Conference Extract] [eCite] [Details] Co-authors: Fernandez-Martos CM; Hanson K; Woodhouse A; Vickers JC
2014	King AE, Fernandez-Martos CM, Hanson K, Woodhouse A, Vickers JC, 'Anaesthetic exposure and dementia: What can we learn from studies in transgenic mice?', Australian Society of Anaesthetists, 1-2 Mar, Hobart, TAS (2014) [Conference Extract] [eCite] [Details] Co-authors: Fernandez-Martos CM; Hanson K; Woodhouse A; Vickers JC
2014	Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM, 'Microfluidic model for mild traumatic brain injury', Proceedings, The 18th International Conference on Miniaturized Systems for Chemistry and Life Sciences, 26-30 October 2014, San Antonio, Texas, United States, pp. 989-992. ISBN 978-0-9798064-7-6 (2014) [Non Refereed Conference Paper] [eCite] [Details] Co-authors: Yap YC; Dickson TC; Breadmore MC; Guijt RM
2012	Blizzard C, King AE, Hosie KA, Dickson TC, 'Site-specific excitotoxin exposure in vivo leads to neuronal excitotoxicity and axonal dysfunction', 32nd Annual Meeting Australian Neuroscience Society, January 2012, Gold Coast, Australia (2012) [Conference Extract] [eCite] [Details] Co-authors: Blizzard C; Hosie KA; Dickson TC
2012	Blizzard C, King AE, Vickers JC, Dickson TC, 'Site specific excitotoxicity: a model of amyotrophic lateral sclerosis', 32nd Annual Meeting Australian Neuroscience Society, January 2012, Gold Coast, Australia (2012) [Conference Extract] [eCite] [Details] Co-authors: Blizzard C; Vickers JC; Dickson TC
2012	King AE, Blizzard C, Mitew S, Dickson TC, 'Investigating the role of interneurons in neurological disease', DANDIS, January, 2012, Queensland, Australia (2012) [Conference Extract] [eCite] [Details] Co-authors: Blizzard C; Mitew S; Dickson TC
2012	King AE, Mitew S, Kirkcaldie MTK, Vickers JC, Dickson TC, 'Investigating the role of inhibition in neurological disease', 32nd Annual Meeting Australian Neuroscience Society, January 2012, Gold Coast, Australia (2012) [Conference Extract] [eCite] [Details] Co-authors: Mitew S; Kirkcaldie MTK; Vickers JC; Dickson TC
2012	Southam K, Blizzard C, Vickers JC, Dickson TC, King AE, 'Modelling site specific excitotixicity in vitro', University of Tasmania Sharing Excellence in Research meeting, September 2012, Hobart, Australia (2012) [Conference Extract] [eCite] [Details] Co-authors: Southam K; Blizzard C; Vickers JC; Dickson TC
2012	Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM, 'Microfluidic culture platform for studying neuronal response to axonal stretch injury', 28th International Symposium on Microscale Bioseparations and Analyse, 21- 24 October 2012, Shanghai, China (2012) [Conference Extract] [eCite] [Details] Co-authors: Yap YC; Dickson TC; Breadmore MC; Guijt RM
2012	Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM, 'Lab on a chip for studying neuronal degeneration', 3rd Australia & New Zealand Micro/Nanofluidics and Bionano Symposium, 12-13 April 2012, New Zealand (2012) [Conference Extract] [eCite] [Details] Co-authors: Yap YC; Dickson TC; Breadmore MC; Guijt RM
2012	Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM, 'Microfluidic culture platform for studying neuronal response to axonal stretch injury', Proceedings of the 16th International Conference on Miniaturized Systems for Chemistry and Life Sciences, October 28 - November 1, 2012, Okinawa, Japan, pp. 1-13. ISSN 1932-1058 (2012) [Conference Extract] DOI: 10.1063/1.4891098 [eCite] [Details] Citations: Scopus - 25 Co-authors: Yap YC; Dickson TC; Breadmore MC; Guijt RM Tweet
2011	Bennett WR, Blackburn NB, King AE, Chung RS, West AK, 'Does metallothionein attenuate mutant SOD1 aggregation in MND', 22nd Symposium on ALS/MND, November 2011, Sydney, Australia (2011) [Conference Extract] [eCite] [Details] Co-authors: Bennett WR; Blackburn NB; Chung RS; West AK
2011	Blizzard C, King AE, Hosie KA, Dickson TC, 'Modelling site-specific excitotoxicity in vivo', 22nd International Symposium on ALS/MND, November 2011, Sydney, Australia (2011) [Conference Extract] [eCite] [Details] Co-authors: Blizzard C; Hosie KA; Dickson TC
2011	Hosie KA, King AE, Blizzard C, Vickers JC, Dickson TC, 'Modelling ALS pathology in vitro', 22nd Symposium on ALS/MND, November 2011, Sydney, Australia (2011) [Conference Extract] [eCite] [Details] Co-authors: Hosie KA; Blizzard C; Vickers JC; Dickson TC
2011	King AE, Herne KE, Boyer K, Orpin P, 'The experience of food insecurity amongst elderly Tasmanians', Food Futures Conference 2011, Conference Proceedings, 22-23 November 2011, Hobart, pp. 1-20. (2011) [Non Refereed Conference Paper] [eCite] [Details] Co-authors: Herne KE; Boyer K; Orpin P
2011	King AE, Hosie KA, Vickers JC, Blizzard C, Dickson TC, 'An in vitro investigation of the role of interneurons in the development of ALS', 22nd Symposium on ALS/MND, November 2011, Sydney, Australia (2011) [Conference Extract] [eCite] [Details] Co-authors: Hosie KA; Vickers JC; Blizzard C; Dickson TC
2011	Yap YC, Dickson TC, King AE, Breadmore MC, Guijt RM, 'Lab-on-a-chip: A novel in vitro model for studying traumatic brain injury', Proceedings of the 11th Asia Pacific International Symposium on Microscale Separations and Analysis, November 2011, Hobart, Australia (2011) [Conference Extract] [eCite] [Details] Co-authors: Yap YC; Dickson TC; Breadmore MC; Guijt RM
2010	Blizzard CA, Chuckowree JA, King AE, Hosie KA, Chapman JA, et al., 'Focal damage to the neocortex induces dendritic structural plasticity', Australian Neuroscience Society/Australian Physiological Society, January, Sydney, Australia (2010) [Conference Extract] [eCite] [Details] Co-authors: Blizzard CA; Chuckowree JA; Hosie KA; Chapman JA; Vickers JC; Dickson TC
2010	Blizzard CA, Chuckowree JA, King AE, Hosie KA, Chapman JA, et al., 'Focal damage to the neocortex induces dendritic structural plasticity', Proceedings of the Dementia, Ageing and Neurodegenerative Diseases Group Conference 2010, 30 January 2010, Sydney, Australia (2010) [Conference Extract] [eCite] [Details] Co-authors: Blizzard CA; Chuckowree JA; Hosie KA; Chapman JA; Vickers JC; Dickson TC
2010	Dickson TC, King AE, Vickers JC, 'Neurodegeneration in ALS and AD: which comes first the axon or the soma?', Australian Neuroscience Society Conference, 31 January - 3 February, Sydney (2010) [Conference Extract] [eCite] [Details] Co-authors: Dickson TC; Vickers JC
2009	Blizzard CA, Chuckowree JA, King AE, McCormack GH, Chapman JA, et al., 'Acute neocortical injury induces axonal sprouting and dendritic remodelling', ASMR National Scientific Conference, Neurogenetics on the Apple Isle, February, Hobart (2009) [Conference Extract] [eCite] [Details] Co-authors: Blizzard CA; Chuckowree JA; McCormack GH; Chapman JA; Vickers JC; Dickson TC
2009	Dickson TC, King AE, Kirkcaldie MTK, Hosie K, Chung RS, et al., 'Novel alpha-internexin pathological alterations in both the spinal cord and brain of the G93A SOD1 model of amytrophic lateral sclerosis', Society for Neuroscience, 17-21 Oct, Chicago, pp. 304.13. (2009) [Conference Extract] [eCite] [Details] Co-authors: Dickson TC; Kirkcaldie MTK; Hosie K; Chung RS; Vickers JC
2009	Dickson TC, King AE, Kirkcaldie MTK, Hosie K, Vickers JC, 'Novel alpha-internexin pathological alterations in both the spinal cord and forebrain of the G93A SOD1 model of Amyotrophic Lateral Sclerosis', Australian Society for Medical Research, 15-17 November, Hobart, Tasmania (2009) [Conference Extract] [eCite] [Details] Co-authors: Dickson TC; Kirkcaldie MTK; Hosie K; Vickers JC
2009	King AE, Dickson TC, Vickers JC, 'Investigating the cause and consequence of axonal pathology in amyotrophic lateral sclerosis', DANDIS Conference, Australian Neuroscience Society, 27 January, Canberra (2009) [Conference Extract] [eCite] [Details] Co-authors: Dickson TC; Vickers JC
2009	King AE, Hosie K, Staal JA, Musgrove RE, Vickers JC, et al., 'Microfluidic investigation of excitotoxin induced ALS-like axonal degeneration', ALS and Other Motor Neuron Disorders, 20th Symposium on ALS/MND, 8-10 December, Berlin, pp. 102. (2009) [Conference Extract] [eCite] [Details] Co-authors: Hosie K; Staal JA; Musgrove RE; Vickers JC; Dickson TC
2009	Musgrove RE, King AE, Dickson TC, 'Alpha-synuclein is a potential neuroprotectant in both wild-type cortical and dopaminergic neurons, but not A53T mutant neurons', 9th International Conference AD/PD, 11-15 March, Prague, Czech Republic (2009) [Conference Extract] [eCite] [Details] Co-authors: Musgrove RE; Dickson TC
2009	Musgrove RE, King AE, Dickson TC, 'Alpha-synuclein upregulation is a neuroprotective response of dopaminergic and cortical neurons', Australian Society for Medical Research, 15-17 November, Hobart, Tasmania (2009) [Conference Extract] [eCite] [Details] Co-authors: Musgrove RE; Dickson TC
2008	Blizzard C, Chuckowree JA, McCormack GH, Chapman JA, King AE, et al., 'Delayed morphological alterations in a subpopulation of interneurons in the peri-wound region following focal damage to the adult rat neocortex', Neuroscience, 15-19 November 2008, Washington DC (2008) [Conference Extract] [eCite] [Details] Co-authors: Blizzard C; Chuckowree JA; McCormack GH; Chapman JA; Vickers JC; Dickson TC
2008	King AE, Dickson TC, Blizzard CA, Foster SS, Woodhouse A, et al., 'Neuron-glia interactions underlying axonal health in an in vitro spinal culture model of relevance to ALS', Amyotrophic Lateral Sclerosis, 19th Symposium on ALS/MND, 3-5 November, Birmingham, pp. 85. (2008) [Conference Extract] [eCite] [Details] Co-authors: Dickson TC; Blizzard CA; Foster SS; Woodhouse A; Chung RS; Vickers JC
2008	Vickers JC, King AE, Blizzard CA, Woodhouse A, Foster SS, et al., 'Murine spinal neurons in vitro develop proximal axonal transport abnormalities and swellings that are similar to early axonal changes in amyotrophic lateral sclerosis', Society for Neuroscience, 15-19 November, Washington, DC (2008) [Conference Extract] [eCite] [Details] Co-authors: Vickers JC; Blizzard CA; Woodhouse A; Foster SS; Chung RS; Dickson TC
2008	Vickers JC, King AE, Chung RS, Foster S, West AK, et al., 'Axonopathy, excitotoxicity and neuronal degeneration in ALS 2008', Australian Neuroscience Society Conference, 27-30 January, Hobart (2008) [Conference Extract] [eCite] [Details] Co-authors: Vickers JC; Chung RS; Foster S; West AK; Chuah MI; Dickson TC
2007	King AE, Dickson TC, Blizzard CA, Foster SS, Chung RS, et al., 'ALS-like axonal pathology in cultured spinal motor neurons', Amyotrophic Lateral Sclerosis, 18th Symposium on ALS/MND, 1-3 December, Toronto, pp. 191. (2007) [Conference Extract] [eCite] [Details] Co-authors: Dickson TC; Blizzard CA; Foster SS; Chung RS; West AK; Chuah MI; Vickers JC
2007	King AE, Dickson TC, Blizzard CA, Foster SS, Chung RS, et al., 'ALS-like pathology in cultured spinal motor neurons following excitoxicity', IBRO International Conference, 12-17 July, Melbourne (2007) [Conference Extract] [eCite] [Details] Co-authors: Dickson TC; Blizzard CA; Foster SS; Chung RS; West AK; Chuah MI; Vickers JC
2006	King AE, Chung RS, Vickers JC, Dickson TC, 'Relationship between the developmental localisation of glutamate receptor subunits in vitro and susceptibility to excitotoxicity', Australian Neuroscience Society Conference, 31 January - 3 February, Sydney (2006) [Conference Extract] [eCite] [Details] Co-authors: Chung RS; Vickers JC; Dickson TC
2006	Vickers JC, King AE, Dickson TC, Chung RS, Chuckowree JA, et al., 'In vitro models of the key pathological changes in axons associated with neurodegenerative disease and acquired brain injury', 4th Congress of Federation of Asian-Oceanain Neuroscience Societies, November, Hong Kong (2006) [Conference Extract] [eCite] [Details] Co-authors: Vickers JC; Dickson TC; Chung RS; Chuckowree JA; Haas MA; Staal JA; Woodhouse A; Blizzard C; West AK; Chuah I; McCormack G

Grants & Funding

Funding Summary

Number of grants

Total funding

$13,769,314

Projects

The Yulgilbar Foundation Professor Bob Williamson PhD Top-up Scholarship (2023 - 2025)$10,000

Description: Top up scholarship and travel award for Laura de Paoli to support PhD students and to travel to a conference to present work and/or potentially set up a collaboration.
Funding: The Yulgilbar Foundation ($10,000)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: King AE; Collins J; De Paoli LF
Period: 2023 - 2025

Siganto Foundation HDR student Career Development Scholarship in dementia research (2023)$10,000

Description: Training and building collaborations for techniques involving super resolution microscopy (SRM) and applying these techniques to induced pluripotent stem-cell (iPSC) derived neurons and post-mortem human tissue, at the University of Cambridge, UK.
Funding: Siganto Foundation ($10,000)
Scheme: Donation - Institutional
Administered By: University of Tasmania
Research Team: Phipps AJ; Dixit D; King AE; Atkinson RAK
Year: 2023

Prevalence and profiles of Isolated REM Sleep Behaviour Disorder (iRBD) in Tasmania - a high-risk prodromal disorder for dementia and neurodegenerative disease (2023)$22,712

Description: This project will determine the prevalence of Isolated REM Sleep Behaviour Disorder (iRBD) in Tasmania. Up to 90% of people with iRBD will progress to a ND, such as dementia with Lewy Bodies and Parkinson's disease, within 10 years of first diagnosis. This makes iRBD one of the highest risk factors for dementia and other ND. The prevalence of this disorder remains unclear, as few people recognise the significance of iRBD symptoms, and few prevalence studies have been conducted. It is estimated that iRBD affects 2% of the population, but there have never been any prevalence studies in Australia. Participants from the ISLAND Sleep Study will be invited to have a sleep study in their home to confirm a diagnosis of iRBD and will also complete several cognitive-motor-olfactory assessments. This project will identify adults in the Tasmanian community who have iRBD and investigate the cognitive, motor and olfactory characteristics associated with progression to dementia and other neurodegenerative disease.
Funding: Clifford Craig Foundation ($22,712)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Alty JE; Bramich S; King AE; Kuruvilla M; Bindoff AD; Noyce A
Year: 2023

Detecting dementia risk by wearing a watch: Evaluation of sleep/wake patterns to identify REM sleep behaviour disorder (RBD) in Tasmania (2023)$9,700

Description: Adults with RBD have a 90% chance of developing dementia or another neurodegenerative disease (ND) within 10 years. However, RBD is difficult to diagnose. This project will evaluate 24-hour actigraphy (activity) watches for detecting probable RBD (pRBD) in Tasmania.
Funding: Royal Hobart Hospital Research Foundation ($9,700)
Scheme: Grant-Incubator
Administered By: University of Tasmania
Research Team: Alty JE; King AE; Kuruvilla M
Year: 2023

A new substrate reduction strategy to treat childhood dementias: Glucosylceramide synthase-targeting antisense oligonucleotides (2023 - 2025)$599,978

Description: Lysosomal storage disorders (LSDs) contribute to the burden of childhood dementia and are characterised by accumulation (storage) of macromolecules, due to loss-of-function mutation of lysosomal enzymes. One treatment strategy for LSDs is substrate reduction therapy, which aims to limit the production of macromolecules to a level at which residual enzyme activity is sufficient to prevent accumulation. Glucosylceramide synthase (GCS) is a widely expressed enzyme that catalyses the first step in synthesis of glycosphingolipids, a lipid that accumulates in many LSDs. Inhibition of GCS using miglustat (Zavesca) is currently approved in some countries to treat several LSDs, however, gastrointestinal side effects, weight loss, and tremor are common, and it has a low ability to transverse the blood-brain barrier limiting its' use for childhood dementia.Here we will develop an approach complementary to pharmacological inhibition of the GCS enzyme, by developing antisense oligonucleotides (ASOs) and testing their ability to decrease expression of GCS and thereby lower glycosphingolipid accumulation. ASOs are an ideal complementary therapy to agents such as miglustat because they target the GCS-encoding mRNA to decrease the amount of enzyme produced, and can exert long-lasting effects throughout the brain when delivered to pre-clinical animal models or humans. We have hypothesised that GCS-trageting ASOs will provide benefit to multiple LSDs that cause childhood dementia, because of close genetic and biochemical association with gylcosphingolipid metabolism or through pre-clinical studies where miglustat and related small molecular inhibitors of GCS have rescued disease-related phenotypes. We will use multiple human cell-based models to determine diseases where GCS-targeting ASOs are effective, and test target engagement in mice. We anticipate GCS-targeting ASOs will bridge the gap to disease-modifying therapies for LSDs and improve care for children with dementia.
Funding: Medical Research Future Fund ($599,978)
Scheme: Grant - Preventative and Public Health Research
Administered By: University of Tasmania
Research Team: Cook AL; Aung-Htut M; Perry SE; King AE; Wilton S; Hewitt A; Ware TL; McIntosh C; Baynam G; Wallis M
Period: 2023 - 2025

Refinement of p75 ECD measurement as a biomarker for clinical trials for MND (2023)$100,000

Description: Our grant aims to improve the measurement of a strong candidate MND biomarker, p75ECD in urine and blood. By developing a more sensitive SIngle MOlecule Array assay we will improve and expand use of urinary p75ECD for clinical trials and improve quantification in the blood. This will pave the way for p75ECD to be used in more widely in clinical trials to determine effective treatments.
Funding: Motor Neurone Disease Research Australia ($100,000)
Scheme: Grant - Innovator
Administered By: Flinders University
Research Team: Rogers ML; King AE; Collins J; Schultz D; Benyamin B
Year: 2023

Alternate drivers of Alzheimer's disease: Are microglia the problem? (2023 - 2026)$326,358

Description: This research aims to understand if microglia are genetically programmed to drive Alzheimers disease progression. Recent studies suggest microglia are highly associated with Alzheimers disease and could potentially be the initiators of disease. We know microglial functional capacity changes with increasing plaque burden (hallmark of AD). Additional evidence demonstrates microglia have innate differences dependent on biological sex. These innate differences in microglia could partially explain why females are twice as likely than males to develop Alzheimers disease. Our innovative research plan combines these past findings to investigate whether transplanting microglia from healthy mice diminishes disease burden. Further, we will examine whether transplanting microglia from Alzheimers disease mice changes neuropathology with ageing. Our study design will investigate these factors in both biological sexes.
Funding: National Foundation for Medical Research and Innovation ($326,358)
Scheme: Grant-Expression of Interest
Administered By: University of Tasmania
Research Team: Ziebell JM; King AE; Doust YV
Period: 2023 - 2026

Identifying older adults in Tasmania with REM Sleep Behaviour Disorder(RBD): the crucial first step towards reducing their high risk of neurodegeneration. (2022)$24,818

Description: Adults with RBD have a 90% chance of developing dementia or other neurodegenerative disease (ND) within 10 years. However, RBD is under-recognised. This project will identify RBD prevalence in Tasmania, characterise its associated features, and offer risk reduction strategies with the long-term aim of decreasing the incidence of ND.
Funding: Royal Hobart Hospital Research Foundation ($24,818)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: Bramich S; Alty JE; King AE; Kuruvilla M
Year: 2022

Developing new tools to diagnose and monitor MND (2022)$98,626

Description: This project aims to develop two new ultrasensitive single molecule array blood biomarker assays for the detection of the neurofilament proteins alpha-internexin and peripherin, which are specific to the central and peripheral nervous systems. We will then test the ability of these blood biomarker assays to detect central versus peripheral nervous system degeneration in mouse models of motor neuron disease and human motor neuron disease cases.
Funding: Motor Neurone Disease Research Australia ($98,626)
Scheme: Grant - Innovator
Administered By: University of Tasmania
Research Team: Collins J; King AE; Rogers ML
Year: 2022

Epidemiology in a dish: using human iPSC to discover common and genotype-specific molecular signatures of the multi-step hypothesis of ALS (2022 - 2025)$999,981

Description: In this project we want to investigate whether genetic risk and environmental interactions cause motor neurons to die and what cellular pathways are activated in response to genetic and environmental risk individually, and combined. We will use human cells to grow motor neurons in a dish, and genetically alter these neurons to carry genes associated with familial or sporadic ALS - this will be modelling the first 'step' in the multistep process. We will then expose these neurons to a variety of environmental factors known to be risk factors for ALS, including cholesterol, neurotoxins and increased cellular activity, that will contribute additional steps in this process. We will examine how the neurons respond to different gene-environment interactions by documenting changes to their shape, activity and function, cellular processes and protein expression, to identify key/signature pathways in these cells that are going wrong in disease. We will correlate our findings in cells to human ALS tissues and ALS mouse models. This work will help us understand how ALS develops and why cells are vulnerable to genetic and environmental interactions.
Funding: FightMND ($999,981)
Scheme: Grant-Discovery
Administered By: University of Tasmania
Research Team: Cook AL; Perry SE; King AE; Atkinson RAK; Phipps AJ
Period: 2022 - 2025

Detecting microvascular injury after stroke using a blood test (2022)$9,820

Description: Pericytes, cells controlling blood flow in the brain, are injured post-stroke. This may increase brain injury and worsen neurological disability. This project will develop a blood test for detecting pericyte injury. This test may be useful for diagnosing blood flow impairments or predicting brain injury and neurological disability post-stroke.
Funding: Royal Hobart Hospital Research Foundation ($9,820)
Scheme: Grant-Incubator
Administered By: University of Tasmania
Research Team: Morris GP; Sutherland BA; Howells DW; King AE; Castley HJ; Courtney J; Collins J
Year: 2022

To die or not to die: What is the mechanism of axon degeneration in ALS? (2022)$99,491

Description: Axons are long processes that allow for communication between our nerve cells and muscles to enable movement. During MND, nerve cell axons degenerate, leading to loss of motor function and mortality; the mechanism of which we do not understand. In this project, we will use human iPSC-derived nerve cells to investigate what pathways are involved in axon degeneration through 'omics' approaches, including RNA-seq and proteomics. By understanding why axons are vulnerable, and what pathways dysfunction during MND, we can design novel therapies to prevent and treat axon degeneration in MND.
Funding: Motor Neurone Disease Research Australia ($99,491)
Scheme: Grant - Innovator
Administered By: University of Tasmania
Research Team: Phipps AJ; Atkinson RAK; Perry SE; King AE; Cook AL
Year: 2022

Pre-familial and early MND biomarker program (2022 - 2024)$499,980

Description: In this collaborative project, we will work with a European Consortium called premodiALS to develop a clinical molecular fingerprint of pre familial MND and early sporadic MND that will provide insight into what occurs to drive MND and allow earlier diagnosis. The project is led by Assoc Prof Mary-Louise Rogers at Flinders University and in collaboration with Prof Paul Lingor (Germany) and Prof Anna King of the University of Tasmania. We will measure fluid signatures of pre familial and early MND and related disorders. Specifically, in Australia we will measure urine, cerebrospinal fluid and blood biomarkers from European and USA pre familial MND and early MND and mimics. The measurements will be at Flinders University, and at the University of Tasmania's Wicking Institute. The collaborative project will be used to build a molecular fingerprint of MND that will not only improve diagnosis, but also provide information on the causes of MND, ultimately leading to effective treatment strategies.
Funding: FightMND ($499,980)
Scheme: Grant-Collaborative Initiative
Administered By: Flinders University
Research Team: Rogers ML; Lingor P; King AE
Period: 2022 - 2024

Acquisition of a VS200 Research Slide Scanner for the College of Health and Medicine (2022)$100,000

Description: The Olympus VS200 Research Slide Scanner enables the imaging of entire tissue sections in an automated manner. It can acquire images from up to six fluorescent channels along with brightfield, dark field and phase contrast, and has objectives up to 100X. The robotic slide loader allows for batch scanning of up to 210 slides at a time and can accommodate multiple sizes of slides up to 4x5 plates for large tissue sections. Our current VS120 slide scanner is already used at a maximum capacity with researchers having to book weeks in advance to scan slides. The VS200 will add further capacity and offers improved capabilities with greater optical resolution, more fluorescent channels, more batch scanning capacity and the ability to scan larger slides. Pairing this with free open source software like QuPath provides high throughput, efficient and highly accurate quantitative workflows that greatly improve productivity.
Funding: Ian Potter Foundation ($100,000)
Scheme: Grant - Medical Research
Administered By: University of Tasmania
Research Team: Sutherland BA; Howells DW; Courtney J; King AE; Dickson TC; Premilovac D; Bye N; Flies AS; Young K
Year: 2022

GreyScan TVD Extension (2021)$146,415

Description: Funding to continue research on the development of the GreyScan TVD-1 system for trace virus detection. A first round of research supported by CSIRO innovations connection funding has completed. Additional work is required to continue the research required for product scope and development.
Funding: GreyScan Pty Ltd ($146,415)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Breadmore MC; Gell DA; King AE; Flies AS; Wilson CR; Flies E; Liu G
Year: 2021

Isogenic iPSC models with CLN3 variants for high throughput drug screening (2021)$49,400

Description: To advance therapeutic strategies for Batten disease, we will use our existing isogenic iPSC models with CLN3 variants to:Aim 1: Measure CLN3-dependent changes in neuronal network activity using multielectrode arrays.Aim 2: Quantify CLN3-dependent changes in lysosomal, mitochondrial and autophagy function in neurons.Aim 3: Identify CNS-penetrant drugs that exhibit efficacy against CLN3-variant associated neuron changes.
Funding: Batten Disease Support and Research Association ($49,400)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Cook AL; Hewitt A; King AE; Perry SE
Year: 2021

Developing biosensors for high throughput screening to detect those at risk of dementia (2021)$119,386

Description: Recently, proteins have been identified in the blood that can act as indicators that a person is at risk of developing dementia or neurodegenerative disease. This opens a window of opportunity for early intervention and preventative strategies. At present these proteins need to be measured using equipment not available to health professionals and the current methods use antibodies as biosensors. Antibodies are unstable, difficult to produce and expensive, and therefore not suited for wide-spread distribution of detection devices. Aptamers are single-stranded oligonucleotide (DNA or RNA) molecules, which can bind to target molecules with high affinity and specificity. They are ideal for use as biosensors in point-of-care devices as they are stable at room temperature and are cheap to produce. Our goal is to develop biomarker detection devices that are suitable for population-based screening. This project will develop aptamers to key biomarker indicators of brain health such as neurofilament light chain and tau.
Funding: Perpetual Trustees ($119,386)
Scheme: Grant-Trust Fund
Administered By: University of Tasmania
Research Team: King AE; Breadmore MC; Gell DA; Collins J; Shigdar S
Year: 2021

Translating Awareness, Literacy, and Knowledge of Traumatic Brain Injury (TALK-TBI) (2021)$999,998

Description: The proposal has outstanding levels of community engagement. The team has allocated time (milestone indicators) and resources (budget) for extended community engagement at all stages of the project making the proposal highly feasible. Additionally, we have already established relationships with Aboriginal and Torres Strait Islander communities. Tasmanian Aboriginal Centre (TAC) and CI Schramm have assisted with the design of the project and TAC have agreed to host at least one Aboriginal health worker for the duration of this project. In addition, TAC has confirmed the transferability of the skills (e.g. communication, analysis, education design) gained from working on this project are highly desirable for future research and education programs.The incidence of TBI in the Aboriginal and Torres Strait Islander communities is almost twice the national average this means urgent attention is needed to increase awareness and educate. Tasmanian Aboriginal Centre (TAC) has indicated to the research team that brain injury awareness and education are a priority for their communities. Our research proposal aims to not only establish awareness of TBI but also the lived experience of those who have sustained a TBI. Accounts can be captured in their language making the applicability to others in the community stronger. These personal accounts may also identify areas of need for specific educational programs, which are culturally appropriate and can be developed in consultation with the local communities.
Funding: Medical Research Future Fund ($999,998)
Scheme: Grant - Traumatic Brain Injury Mission
Administered By: University of Tasmania
Research Team: Ziebell JM; Cook PS; Doherty KV; Eccleston CEA; Schramm TA; Fitzgerald M; Padgett C; King AE; Vickers JC
Year: 2021

ICG - GREYSCAN PTY LTD (2020)$259,020

Description: With GreyScan will repurpose the ETD-100 trace explosives system to detect viruses and create a new product range, TVD 1
Funding: GreyScan Pty Ltd ($259,020)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Breadmore MC; King AE; Karupiah G; Flies AS; Wilson CR; Flies E; Gell DA
Year: 2020

The ISLAND Project (2020 - 2024)$300,000

Description: The ISLAND Project has three overall objectives:1. Establish the incidence of dementia across our community.2. Build awareness of dementia and its risk factors within the Tasmanian population.3. Undertake a community-engaged public health program as a partnership to reduce dementia risk, and hence the age specific incidence of dementia across Tasmania.
Funding: Terry and Maureen Hopkins Foundation ($300,000)
Scheme: Donation - Institutional
Administered By: University of Tasmania
Research Team: Vickers JC; King AE
Period: 2020 - 2024

Blood-based biomarkers for neurodegeneration dementia (2020 - 2022)$449,386

Description: This project will characterise a blood biomarker of neurodegeneration for prognostic and diagnostic value to predict cognitive decline and dementia.
Funding: Royal Hobart Hospital Research Foundation ($449,386)
Scheme: Grant-Major Project
Administered By: University of Tasmania
Research Team: Collins J; Vickers JC; King AE; Alty JE; Cooper PD
Period: 2020 - 2022

Microfluidic models of the CNS: Understanding cells, circuits & synapses (2020 - 2022)$545,563

Description: The critical importance of understanding how the brain functions is evidenced by international investment in thisarea of research. For example, in the US, BRAIN (Brain Research through Advancing InnovativeNeurotechnologies) has been supported with $1-3 billion, while in Europe the 'Human Brain Project' is supportedwith $1.5 billion. This proposal falls directly within the scope of these with its focus on new platform technology tounderpin fundamental molecular studies of neuronal circuits. It is in the national interest of Australia to undertakeinternationally leading cross-disciplinary research in this area, a position confirmed in the Academy of Sciencecoordinated Think Tank on Inspiring smarter brain research in Australia. Being the first to develop this newplatform technology, will allow Australian researchers to be at the forefront of determining the mechanismsunderlying neurodegenerative diseases, and the development of new treatments. In addition, direct financialbenefit could be obtained through the technology, for example, through licensing novel microchamber designs.
Funding: Australian Research Council ($545,563)
Scheme: Grant-Discovery Projects
Administered By: University of Tasmania
Research Team: Dickson TC; King AE; Cook AL
Period: 2020 - 2022
Grant Reference: DP200103193

A potential metabolic-targeted therapeutic for Amyotrophic lateral sclerosis (ALS): Leptin (2020 - 2022)$222,212

Description: This project looks at the effect of leptin resistance induced by high path diet on the neurodegenerative pathways induced by TDP-43.
Funding: Fundacion Hospital Nacional de Paraplejicos ($222,212)
Scheme: Consortium Agreement
Administered By: Fundacion Hospital Nacional de Paraplejicos
Research Team: Fernandez Martos C; King AE; Del Olmo Izquierdo N; Sreedharan J; Vickers JC; Atkinson RAK
Period: 2020 - 2022

Why do we have SARM 1 protein if knocking it out prevents axons degenerating? (2020 - 2022)$597,651

Description: Loss of axonal connections between nerve cells results in reduced cognitive function and memory loss. Axons, like cells, can orchestrate their own death mechanisms and the SARM1 protein mediates Wallerian degeneration the best known axon death pathway. It is not yet understood, why neurons have evolved to have this axon degeneration pathway; whether it is aberrantly activate in neurodegenerative disease or whether it protects the nervous system from adverse nerve cell connections. By using a combination of methods, including axon injury and neurodegeneration mouse models, and human stem cell research, we will identify the exact role of SARM1 in the response to injury and neurodegeneration and determine whether blocking axons from this protein is beneficial or harmful. Our team is comprised of world leaders in investigating axon pathology, degeneration and regeneration in neurodegenerative disease and injury, and outcomes of this research will advance treatment of diseases such as dementia and motor-neuron disease.
Funding: National Health & Medical Research Council ($597,651)
Scheme: Grant-Ideas
Administered By: University of Tasmania
Research Team: King AE; Canty A; Cook AL; Perry SE
Period: 2020 - 2022
Grant Reference: 1187156

Investigating stress related therapeutic targets for Alzheimers disease in human neuronal cells (2020 - 2021)$75,000

Description: This study will determine how glucocorticoid stress signaling interacts with amyloid beta and tau proteins in human neuronal cells.
Funding: Dementia Australia Research Foundation Ltd ($75,000)
Scheme: Grant-Dementia Grants Program
Administered By: University of Tasmania
Research Team: Sinclair D; King AE
Period: 2020 - 2021

PhD top-up - Ellie Bucher (2019 - 2021)$30,000

Description: Project title: Excitatory-Inhibitory relationships in cerebral cortex affected by the pathology of Alzheimer's disease'.
Funding: The Yulgilbar Foundation ($30,000)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: King AE; Kirkcaldie MTK; Bucher EA
Period: 2019 - 2021

Proteomic analysis of exosomes from iPS cell-derived neurons with mislocalised TDP-43 (2019)$99,665

Description: Our overarching hypothesis is that TDP-43 mislocalisation leads to altered axonal and exosomal protein expression, and which may underpin the mechanism of TDP-43 pathological spread leading to neurodegeneration of motor circuits in ALS. To begin testing this hypothesis, we have designed experiments to address three Specific Aims:Aim 1: To characterize human iPS cell-based models of TDP-43 mislocalisationAim 2: To quantify proteins differentially expressed in axons and exosomes of iPS cell-derived neurons with and without TDP-43 mislocalisationAim 3: To quantify transmission of TDP-43 mislocalisation and altered phosphorylation in a human cerebral organoid model
Funding: Motor Neurone Disease Research Australia ($99,665)
Scheme: Grant - Innovator
Administered By: University of Tasmania
Research Team: Cook AL; King AE; Atkinson RAK; Perry SE; Hewitt A
Year: 2019

HDAC6 inhibition to rescue axon degeneration in ALS (2019 - 2023)$997,046

Description: We will test an HDAC6 inhibitor in models of ALS. We will investigate the HDA6 inhibitor activity of novel compounds
Funding: FightMND ($997,046)
Scheme: Grant - Drug Development Grant
Administered By: University of Tasmania
Research Team: King AE; Cook AL; Guven N; Van Den Bosch L; Dickson TC; Blizzard C; Vickers JC; Smith JA; Alty JE; Leung JY; Perry SE
Period: 2019 - 2023

Determining brain health by analysing the blood: development of an aptamer based point of care device (2019)$9,350

Description: We will develop techniques for making aptamer (oligonucleotide) biosensors to be used in biomarker detection in neurodegenerative disease.
Funding: University of Tasmania ($9,350)
Scheme: Grant-Research Enhancement Program
Administered By: University of Tasmania
Research Team: King AE; Shigdar S; Breadmore MC
Year: 2019

Do Renshaw cells have a role in amyotrophic lateral sclerosis disease progression (2019)$15,814

Description: Amyotrophic lateral sclerosis (ALS) is a debilitating disease that results in the degeneration and eventual death of motor neurons in the brain and spinal cord. Currently, there are no effective treatments to slow or stop disease progression, and as such, patients experience a rapid progression of deteriorating motor symptoms prior to their death. We do not have a solid understanding of what causes motor neurons to be especially vulnerable to degeneration, however, we know that an increase in motor neuron activity, drives the disease forward. To better understand why motor neurons are targeted to become over active, we need to broaden our investigation of ALS mechanisms to other cell populations within motor circuits to examine how these cells might contribute to the biological mechanisms causing the disease. This project focuses on investigating how a population of spinal cord cells, known as Renshaw cells, might contribute to motor neuron degeneration and ALS disease mechanisms. We will use experimental mouse models that i) target Renshaw cells and ii) mimic ALS disease processes, and establish novel techniques to grow spinal cord cells in a dish. We will use these methods to identify and investigate the vulnerability and degeneration of Renshaw cells in response to ALS disease mechanisms, and what consequence this has on motor neuron degeneration.
Funding: University of Tasmania ($15,814)
Scheme: Grant-Research Enhancement Program
Administered By: University of Tasmania
Research Team: Perry SE; Atkinson RAK; King AE
Year: 2019

Developing a protocol to predicting health outcomes through oral microbes (2018)$9,917

Description: Older people in residential aged care are vulnerable to aspiration pneumonia, which is a primary reason for hospitalisation. Links have been drawn between this vulnerability and poor oral hygiene, prompting interventions in teeth cleaning. To determine the effectiveness of teeth-cleaning interventions objective measures are needed, such as microbiological testing. The goal of this study is to develop and validate a microbiological measure of effective oral hygiene to be used in a large-scale intervention targeting oral hygiene in residential aged care facilities.
Funding: University of Tasmania ($9,917)
Scheme: Grant- Research Enhancement Program
Administered By: University of Tasmania
Research Team: Bettiol SS; Crocombe LA; Goldberg LR; King AE
Year: 2018

Developing a robust laboratory protocol for analyzing oral swabs for pathogenic or key microbiological flora (2018)$8,122

Description: The aim of this subproject is to develop and validate a qPCR protocol for analysing solutions derived from swabs of oral tissue to quantify numbers and distribution of pathogenic bacterial species within a complex microbiological ecology. This protocol will later be used to determine the change in type and load of oral microorganisms following a period of daily oral hygiene.
Funding: Australian Dental Health Foundation ($8,122)
Scheme: Grant-Wrigley Foundation Community Service Grant
Administered By: University of Tasmania
Research Team: Crocombe LA; Bettiol SS; Goldberg LR; King AE
Year: 2018

Detecting Biomarkers of Brain Health in Dementia (2018 - 2021)$720,144

Description: Neurons signal to each by sending electrical impulses along their axons to the connections between neurons, the synapses. Loss of this signalingin thought to be the underlying cause of the clinical symptoms of dementia, correlating closely with cognitive decline. This loss of connectivityis accompanied by various types of pathology in the brain such as accumulation of extracellular beta amyloid and intracellular tau, although theconnection between pathology and neurodegeneration is not yet clear. One of the biggest challenges we face in developing treatments fordementia is the need to monitor the changes that are going on inside the brain of living individuals. In order to do this, we need to developbiomarkers; measurable biological indicators of a disease process. While there has been significant progress in the development of biomarkers toindicate the presence of pathology in the brain, biomarkers of neurodegeneration, which may be a correlate of brain health, are lacking. I have adeveloping international reputation in investigating the mechanisms by which nerve cells lose their connections in dementia, with the goal ofidentifying targets for therapeutic intervention. Capitilizing on my current expertise I propose to bring together preclinical work in animalmodels of dementia with a human cohort study to fully characterize blood based biomarkers that reflect the neuritic and synaptic changesoccurring in the brains of people with dementia. Working with Professor Michael Breadmore (University of Tasmania, ACROSS), an international leader in the development of portable analytical devices, I will then develop a point of care analysis tool to monitor brain health inboth rodent models and people at risk of dementia. Working at the Wicking Dementia Research and Education Centre, a multidisciplinary teamacross neuroscience and health services, I am well placed to bridge the gap between research and industry, and to lead a new directive indementia research.
Funding: National Health & Medical Research Council ($720,144)
Scheme: Fellowship - Boosting Dementia Research Leadership
Administered By: University of Tasmania
Research Team: King AE
Period: 2018 - 2021
Grant Reference: 1136913

Towards Axon Protection in ALS (2018)$98,470

Description: Nerve cells communicate with each other and their targets, such as muscle, via long processes called axons. In motor neuron disease these nerve cell processes degenerate and are lost, resulting in a loss of movement. Several mechanisms or axon degeneration have been recently identified, but we don't know which of these mechanisms is involved in motor neuron disease. In this project, we will use two models to determine which mechanisms of axon degeneration are involved in nerve process loss in motor neuron disease. This will allow us to determine which molecules to target for therapeutic intervention.
Funding: Motor Neurone Disease Research Australia ($98,470)
Scheme: Grant-In-Aid
Administered By: University of Tasmania
Research Team: King AE; Perry SE; Leung JY
Year: 2018

How does stress impact pathological processes in Alzheimer's disease? (2018)$50,000

Description: This study will determine how glucocorticoid stress signaling influences Aβ processing (and vice versa) in primary neurons from APP/PS1 transgenic mice and wildtype controls.
Funding: Dementia Australia Research Foundation Ltd ($50,000)
Scheme: Grant-Dementia Grants Program
Administered By: University of Tasmania
Research Team: Sinclair D; King AE; Vickers JC
Year: 2018

Advanced high resolution biomolecular analysis facility for Tasmania (2018)$350,790

Description: This proposal seeks support for an advanced, multi-purpose mass spectrometry platform for high-throughput and targeted biomolecular analysis, including proteomics and metabolomics. The intended purpose of the proposed infrastructure is to provide a centralised state-of-the-art facility that supports internationally competitive research programs in plant science, agricultural research, food safety, animal and human health research and separation science at the University of Tasmania (UTAS) and within the broader Tasmanian scientific community. Theanticipated benefit is a greatly enhanced capacity for leading edge research of national significance that alignswith the UTAS strategic research plan and national priorities.
Funding: Australian Research Council ($350,790)
Scheme: Grant-Linkage Infrastructure
Administered By: University of Tasmania
Research Team: Smith SM; Paull B; Woods GM; King AE; Wilson RR
Year: 2018
Grant Reference: LE180100059

Integrated Biomarker Discovery and Tissue Banking Facility (2018)$1,174,000

Description: Establishment of an integrated biomarker discovery and tissue bank facility at the Medical Sciences Precinct, University of Tasamania. This facility will include biomarker analyser and validation systems, high-throughput qPCR machines, a genealogical and biospecimen management system and a managed tissue bank.
Funding: University of Tasmania ($1,174,000)
Scheme: null
Administered By: University of Tasmania
Research Team: Dickinson JL; King AE
Year: 2018

Could gut microbiota influence cognitive decline and Alzheimer's disease? (2018)$0

Description: This pilot grant will map gut microbiota in three populations:A) Individuals with a clinical diagnosis of dementia: Individuals identified by a clinician as living with dementia will be recruited (n=20). These individuals must be residing in the community as gut microbiota alterations are known to be dependent on the environment (13).B) Spousal caregivers for those living with dementia: Carers of individuals living with dementia are six times more likely to develop dementia (14). Stress is a leading theory for this occurrence, however shared gut microbiota is a potential unexplored link. This group potentially represents the pre-clinical population where alterations to gut microbiota are occurring before symptoms are established (n=20).C) Spousal caregivers providing informal care to someone who does not have dementia: A cohort of individuals providing care to a spouse living with a chronic illness will be recruited (n=20). This group will provide evidence as to whether the disease and/or gut microbiota influence AD development.By determining the gut microbiota diversity in these populations, we will begin to understand whether gut microbiota influences cognitive decline and dementia. Initially this will be a cross-sectional study but if data are promising then it will lead to a longitudinal study.
Funding: uBiome, Inc. ($0)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Ziebell JM; King AE; Lea EJ
Year: 2018

Can microglia priming influence neurodegeneration? (2018)$10,000

Description: Inflammation has been implicated in premature ageing of the brain and the development of neurological disease (1). Microglia are the inflammatory cells of the brain, and currently it is unclear whether they are active (driving pathology) or passive (a bystander) in the ageing and neurodegenerative processes. In response to disturbances in the microenvironment microglia are capable of secreting both pro- and anti-inflammatory cytokines to restore homeostasis. With subsequent disturbances, microglia mount an exaggerated response, due to priming. Increasing age impedes microglia's ability to perform the most essential of homeostatic functions. At this time microglia are known as dystrophic; stuck in a pro-inflammatory phenotype. Understanding this switch to a pro-inflammatory state may aid in preventing the effects of ageing through modulation of microglial activity and offers a novel target for therapy to slow the progression of neurological disease. For this to be effective, we must first define the precise roles of microglia in ageing and neurodegeneration. By determining microglial phenotype throughout disease progression we can gain insight into their role in disease pathology.
Funding: University of Tasmania ($10,000)
Scheme: Grant-Strategic Research
Administered By: University of Tasmania
Research Team: Ziebell JM; King AE; Lea EJ
Year: 2018

Investigating Batten disease-causing CLN3 mutations in patient-specific stem cells and neurons (2017)$24,898

Description: Batten disease is a rare childhood disease that results in dementia and a progressive loss of vision, and which can be due to mutation of the CLN3 gene. Using advances in stem cell technologies, we will study how the Batten disease-causing mutations in CLN3 differently affect nerve health.
Funding: Royal Hobart Hospital Research Foundation ($24,898)
Scheme: Grant-Establishment
Administered By: University of Tasmania
Research Team: Cook AL; Hewitt A; King AE; Ware TL
Year: 2017

CRISPR/Cas gene editing of Batten disease genes in patient-specific stem cells (2017)$51,411

Description: Batten disease is a rare childhood disease that results in dementia and a progressive loss of vision, and which can be due to mutation of the several genes, including CLN2 and CLN3. Using advances in stem cell technologies, we will study how the Batten disease-causing mutations in these genes differently affect nerve health.
Funding: Batten Disease Support and Research Association ($51,411)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Cook AL; Hewitt A; King AE; Pebay A; Grubman A
Year: 2017

Improving the Oral Health of Tasmanians in Residential Aged Care (2017)$28,336

Description: This project seeks to improve and maintain the oral health of people who move into residential aged care by providing an objective way to document they are receiving effective oral care. The project is a staff initiative. It is the result of a suggestion by staff at the Fred French and Peace Haven Homes of Masonic Care Tasmania, Inc. during their participation in a current federally-funded initiative with researchers at the University of Tasmania. The specific aim of the funded project is to decrease cases of aspiration pneumonia through testing the effectiveness of a new model of oral health care. Staff have suggested the value of adding an objective way to obtain and regularly analyse oral bacteria - and this is the focus of the project we are presenting to the TCF.Residents in aged care are particularly vulnerable to aspiration pneumonia. This type of pneumonia is directly related to poor oral health. Poor oral health alters the type of bacteria growing in the mouth and throat. If residents have a swallowing problem (dysphagia), they are more likely to aspirate material into their lungs. If residents with dysphagia have poor oral health, they aspirate pathogenic bacteria and this greatly increases the likelihood of aspiration pneumonia, resulting in unplanned hospitalisations and death. In Australia, the cost burden of this acquired pneumonia has been estimated at more than $500 million each year. The funded model being evaluated has three essential components: (i)Increase staff knowledge - with the support of a Community of Practice including residents, healthcare professionals, community members, residential community leaders, legislators (to bridge the practice-policy divide), and on-site supervised dental/oral health therapy, nursing, and medical students,(ii)Provide daily evidence-based oral care - a 3-month period of 2-minutes of teeth cleaning after meals using timed electric or regular toothbrushes, or daily denture care. For residents who cannot adjust to the electric toothbrushes, staff are developing 2-minute strategies for using regular toothbrushes, e.g., brushing to a series of enjoyed and resident selected 2-minute recorded songs,(iii)Monitor compliance - from their ongoing experience, staff have suggested the potential advantages of the proposed objective and regular analysis of oral bacteria.Increasing and maintaining residents' oral health will decrease the load of pathogenic oral bacteria and thus decrease residents' risk for developing aspiration pneumonia. Understanding the type of pathogenic oral bacteria that are associated with aspiration pneumonia and ill health will further support staff to provide daily oral care. Bacteria will be gathered from non-invasive swabs of tissue from residents' gum, hard palate, cheek, and tongue. Results of these regular analyses will reinforce how effective oral care can reduce the clinical indications of aspiration pneumonia and ill health and the personal and economic consequences of unplanned transfers or admissions to hospital. This cost-effective model can then be easily implemented in any residential aged care community.
Funding: Tasmanian Community Fund ($28,336)
Scheme: Grant
Administered By: University of Tasmania
Research Team: Goldberg LR; Crocombe LA; Bettiol SS; King AE; Legge S
Year: 2017

Staying connected: determining targets to protect neuronal circuitry in ALS (2017)$97,119

Description: Amyotrophic lateral sclerosis (ALS) is characterized by degeneration and loss of nerve cell processes. The resulting loss of connectivity is likely to be the key contributor to the clinical symptoms of disease and is evident from the substantial axonal pathology present. In this project we will investigate mechanisms of axonopathy resulting from pathologic TDP-43, a key contributor to disease. We will utilize a novel of of axon degeneration in the cisual system which allows us to directly probe changes in the axon.
Funding: Motor Neurone Disease Research Australia ($97,119)
Scheme: Grant-In-Aid
Administered By: University of Tasmania
Research Team: King AE; Kirkcaldie MTK
Year: 2017

Does plasticity drive Alzheimers disease and can sleep help (2017)$94,140

Description: This study seeks to elucidate a potential causal mechanism for Alzheimer's disease: that plasticity drives disease pathology, and that sleep compensates for these effects of plasticity in a manner which declines with age. The study will manipulate levels of cortical plasticity and the duration of sleep in a transgenic rodent model, the APP/PS1 mouse, and track the resulting development of pathology.
Funding: The Mason Foundation ($94,140)
Scheme: Grant-Judith Jane Mason & Harold Stannett Williams
Administered By: University of Tasmania
Research Team: Kirkcaldie MTK; King AE; Vickers JC
Year: 2017

Identifying the role of oligodendrocytes in disease onset and the progression in Amyotrophic Lateral Sclerosis (2017)$99,923

Description: Neurons have been the main focus of research and the target of therapeutic development in Amyotrophic Lateral Sclerosis (ALS). Previous studies have display evidence showing the potential involvement of other non-neuronal cells in the disease progression including astrocytes, microglia and oligodendrocytes. Although loss of myelin and oligodendrocyte degeneration has been identified, it has been mostly regarded as a secondary event occurring as a response to the degeneration of axons. Our recent studies have shown evidence supporting the potential active role ofTDP43 (TAR-DNA-binding protein 43) in oligodendrocytes development in vitro. These results suggested that alteration of TDP43 expression could induced oligodendrocytes pathology in ALS and is possible to have an active contribution to disease progress in ALS as well as the onset of the disease.
Funding: Motor Neurone Disease Research Australia ($99,923)
Scheme: Grant-In-Aid
Administered By: University of Tasmania
Research Team: Leung JY; King AE
Year: 2017

How do microglia-synapse dynamics change with Alzheimer's disease? (2017)$50,000

Description: This project explores the emerging role of microglia in facilitating changes to neuronal connections, synaptic plasticity or the ability of the brain to remodel throughout the lifespan in response to a changing environment. Using state of the art imaging techniques, this project will explore microglia-synapse interactions in real time, to elucidate the role microglia play in synaptic plasticty in Alzheimer's disease and throughout ageing.
Funding: Dementia Australia Research Foundation Ltd ($50,000)
Scheme: Grant-Dementia Grants Program
Administered By: University of Tasmania
Research Team: Ziebell JM; Canty A; King AE
Year: 2017

Bioplatforms Australia (BPA) - collaborative research (2016)$15,000

Description: Funds will be used to procure services from BPA that will support proteomics and research projects on, respectively, molecular mechanisms of DFTD and the physiological response of diatoms to environmental stresses.
Funding: Bioplatforms Australia Ltd ($15,000)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: Wilson RR; Foo E; King AE; Tovar Lopez CD; Martin AR
Year: 2016

A mouse model of mild maternal iodine deficiency and its effect on brain structure (2016)$35,000

Description: Establishinga mouse model of mild gestationaliodine deficiency to study its effects on brain structure and function.
Funding: Brain Foundation ($35,000)
Scheme: Grant-Research
Administered By: University of Tasmania
Research Team: Kirkcaldie MTK; King AE; Vickers JC; Burgess JR; Hynes K
Year: 2016

The Tasmanian Healthy Brain Project: a longitudinal intervention study to reduce the risk of ageing-related cognitive decline and dementia (2016 - 2020)$878,790

Description: It has been estimated that between 30 and 50% of dementia cases may be preventable by addressing modifiable risk factors such as vascular factors and complex mental stimulation. Increasing levels of education at a younger age have been associated with decreased risk of developing dementia in older ages, leading to the suggestion that 'building' cognitive reserve may provide greater resilience to dementia. The Tasmanian Healthy Brain Project (THBP) is a large scale prospective trial that examines whether the 'real-world' intervention of university-level study, as a form of complex mental stimulation, in older adults may provide benefits to cognitive resilience, so as to reduce ageing-related decline in cognitive performance, and reduce the risk of dementia. The initial phase of the THBP (2010-2015) involved identifying genetic interactions that may modify risk of ageing-related cognitive decline and mediate the benefits of engagement in complex mental stimulation. In addition, the THBP has developed constructs to measure prior and current levels of cognitive reserve and performance. The proposed project will realise the long term outcomes of the THBP to determine how a university course-based intervention may affect cognitive capacity through ageing and if it may effectively protect individuals from significant decline and dementia. Furthermore, we will determine how common variations in genes linked to brain plasticity, such as brain-derived neurotrophic factor (BDNF) gene, may modify how an individual gains potential benefit from the intervention. In this regard, a genetic profile comprised from BDNF and apolipoprotein E polymorphisms, may also predict those at greatest risk of dementia. Finally, we will investigate whether BDNF protein levels in blood may serve as a biomarker for the effects of the intervention and/or as a potential indicator of relative risk or protection from significant cognitive decline.
Funding: National Health & Medical Research Council ($878,790)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: Vickers JC; Summers MJ; Valenzuela M; Summers JJ; King AE; Robinson AL; Srikanth V
Period: 2016 - 2020
Grant Reference: 1108794

PhD top-up - Kelsey Hanson (2015 - 2017)$30,000

Description: The overall aim of this project is to examine mechanisms of axon degeneration in Alzheimer's disease to trial axonal and synaptic protective strategies in vivo and in vitro.
Funding: The Yulgilbar Foundation ($30,000)
Scheme: Contract Research
Administered By: University of Tasmania
Research Team: King AE; Hanson K
Period: 2015 - 2017

Microfluidic technology to help understand physical damage to brain cells (2015 - 2017)$415,500

Description: Understanding the organisation, structure and mechanisms of the human brain and nervous system remains one of the biggest challenges of science. This project will develop a new cell culture platform to form defined molecular networks of brain cells and to monitor changes throughout the network in response to a small localised injury within the network. This innovative platform will be used to help understand changes within cells in response to physical damage to networks of brain cells. This is one of the major causes of death and disability in developed nations, and is identified as a risk factor for a range of neurodegenerative diseases including Alzheimer's, Parkinson's and motor neuron disease.
Funding: Australian Research Council ($415,500)
Scheme: Grant-Discovery Projects
Administered By: University of Tasmania
Research Team: Dickson TC; King AE; Breadmore MC; Guijt RM
Period: 2015 - 2017
Grant Reference: DP150100998

INHIBITORY REGULATION OF MOTOR NEURONS: A NEW TARGET MECHANISM FOR ALS ? (2015)$86,329

Description: There is considerable evidence from many areas of clinical and basic medical research that in MND motor neurons may be dying due to a toxicity that is triggered due to their over activity - known as excitotoxicity. There is new evidence that this toxic cascade may initially be triggered by the death or dysfunction of another type of neuron in the brain - the interneuron. Interneurons are critical regulators of motor neuron activity and modulators of the balance that is essential for normal brain function. Research has developed a method of specifically growing interneurons and/or motor neurons, derived from transgenic mice developed to model MND, in primary culture. This highly specific 'brain in a dish' approach will allow us to determine if the presence of abnormal or pathogenic interneurons can lead to abnormal motor neuron function and pathology. Not only would these studies provide important insight into the mechanisms responsible for ALS, but they would also provide a high throughput model for later assessing potential therapeutic interventions.
Funding: Motor Neurone Disease Research Australia ($86,329)
Scheme: Grant-In-Aid
Administered By: University of Tasmania
Research Team: Dickson TC; King AE
Year: 2015

Axon degeneration and axon protection in CNS disease and injury (2015 - 2017)$377,077

Funding: National Health & Medical Research Council ($377,077)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: King AE; Vickers JC; Canty A
Period: 2015 - 2017
Grant Reference: 1085221

Investigating the role of oligodendrocytes in frontotemporal lobar dementia (FTLD) (2015)$50,000

Description: Current research on frontotemporal-lobar dementia (FTLD) is focused on the detrimental effect of the pathological proteins in neurons. However, in FTLD, protein aggregates are also found in oligodendrocytes, which are responsible for myelinating and supporting axons. FTLD has a strong genetic and pathological links with Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neuron disease. In ALS there is now substantial evidences suggesting that oligodendrocyte degeneration is involved in disease pathogenesis potentially as a primary pathologic mechanism. Both FTLD and ALS share the common pathologic protein, TDP-43, which is found to aggregate in oligodendrocytes, hence it is feasible to suggest a role for oligodendrocyte dysfunction in FTLD. Studies in ALS tissue and mouse models have suggested that defects in the differentiation and maturation of oligodendrocytes as well as their ability to myelinate axons may contribute to the disease. This proposed study aims to establish the role of oligodendrocyte dyfunction in FTLD with a focus on determining the potential role of TDP-43 in the differentiation and remyelination process of oligodendrocytes. This will allow us to have a better understanding in the pathogenesis of FTLD as well as identifying new therapeutic targets for treatments.
Funding: Dementia Australia Research Foundation Ltd ($50,000)
Scheme: Grant-Dementia Grants Program
Administered By: University of Tasmania
Research Team: Leung JY; King AE
Year: 2015

The role of ALS/FTLD proteins in axon function and degeneration in disease (2014)$89,710

Description: By achieving the following aims this project will investigate the role of TDP-43 and other ALS/FTLD proteins in the normal function of the axon and determine how this may contribute to the pathogenesis of disease. Aim 1: to determine the normal localization of TDP-43 and other ALS/FTLD proteins Aim 2: to determine the effect of protein overexpression or knockdown on the axonal proteome (proteomic analysis) and the expression of axonal mRNA. Aim 3: to determine the effect of directing ALS/FTLD proteins to the axon. Aim 4: to investigate the effect of TDP43 and mutants expression on axons in vivo in a retinal model Aim 5:Determine if mutant TDP-43 can be transferred from the axon to oligodendrocytes.
Funding: Motor Neurone Disease Research Australia ($89,710)
Scheme: Grant-In-Aid
Administered By: University of Tasmania
Research Team: King AE; Vickers JC
Year: 2014

The role of FTLD proteins in neurite health, function and dysfunction (2014 - 2016)$90,000

Description: In the last seven years a number of proteins have been identified that are pathologically or genetically associated with Frontotemporal Lobe Degeneration including TDP-43, FUS, C9ORF72 and progranulin. As ubiquitously expressed proteins it has been difficult to assess the role these proteins play in disease, particularly associated with ageing. This project proposes that the disease-associated roles are likely to stem from functions that are specific to neurons and/or glial cells. Accumulating evidence suggests that many of these proteins are involved in neurite outgrowth and cytoskeletal maintenance. This project will use a threefold approach to investigate the role of FTLD proteins in disease. First, it will utilize novel primary cell culture techniques that allow compartmentalization of the neuron to probe axonal and somatodenditic mechanisms. Second, it will utilize an in-vivo intraocular injection model to rapidly examine the effect of mutant and non-mutant proteins on downstream connectivity. Finally, it will investigate neurite pathology in human tissue. This project will provide mechanistic insight into the role of FTLD proteins in disease.
Funding: Dementia Australia Research Foundation Ltd ($90,000)
Scheme: Grant-Scholarship
Administered By: University of Tasmania
Research Team: King AE; Atkinson RAK; Vickers JC
Period: 2014 - 2016

Axon protection in Alzheimer's disease (2014)$59,097

Description: Alzheimer's disease (AD) affects approximately 11% of the population over 65 years and up to 50% of individuals over 85 years and is now the 3rd major cause of death in Australia. In the absence of effective therapeutic intervention it is imperative that we renew our research efforts along novel and innovative lines to prevent, palliate and/ or reduce this condition. One of the key features of AD is the degeneration of the long nerve processes or axons. These are susceptible to damage and this can result in nervous system disconnection and failure even in the absence of cell loss. My research focuses on understanding why axons degenerate in neurodegenerative disease with the aim of finding effective therapeutic agents to prevent this loss. Due to our lack of mechanistic insight into axon degeneration mechanisms, there are currently no therapeutic drugs that target axon degeneration, and this could be one reason to account for the failure of many therapeutic agents that provide only neuronal protection. Therefore axon protection strategies may offer promise in preventing or delaying the ongoing clinical symptoms of the disease. To address this important issue, I have developed a novel cell culture technique that uses microfluidic technology to separate neuronal axons from the soma. This allows us to probe the cellular mechanisms of axon degeneration in conditions related to AD. Using these novel in vitro techniques I have begun to unravel some of these mechanisms and identify some potential points of intervention. Specifically, I have examined axon degeneration mechanisms following excitotoxicity, which results from overstimulation of neurons. Excitotoxicity is one of the key causes of nerve cell degeneration in AD. My work has shown that excitotoxicity causes axons to degenerate and that destabilization of microtubule proteins is an early event in this degeneration. Importantly, stabilizing microtubules with drugs such as taxol and epothilone D prevents axon degeneration following excitotoxicity in our cell culture model. Taxol and epothilone D are both agents that are currently approved for use in the treatment of cancer. The next step is to test whether these agents can block axon degeneration in animal models. In order to do this I will use two models. Firstly I will use an in vivo model of axon degeneration induced by excitotoxicity. This will be used to directly confirm that microtubule stabilization with epothilone D can protect axons from degeneration following excitotoxicity in vivo. Secondly I will use a mouse model of AD which develops axon pathology and for which excitotoic mechanisms are implicated. This AD will be treated with Epothilone D and pathology examined as well as cognitive function. This project will provide preliminary data to pave the way to expanding the project by obtaining significant funding from national research funding schemes such as NHMRC.
Funding: Equity Trustees Limited ($59,097)
Scheme: Grant
Administered By: University of Tasmania
Research Team: King AE; Canty A; Fernandez-Martos CM
Year: 2014

Interneuron dysfunction in Amyotrophic Lateral Sclerosis: A new target for potential therapeutics? (2013)$83,435

Funding: Motor Neurone Disease Research Australia ($83,435)
Scheme: Grant-in-Aid Zo-ee MND Research
Administered By: University of Tasmania
Research Team: Dickson TC; King AE
Year: 2013

Axonal protection in ALS (2013)$78,307

Funding: Motor Neurone Disease Research Australia ($78,307)
Scheme: Grant-In-Aid
Administered By: University of Tasmania
Research Team: King AE; Blizzard C; Dickson TC
Year: 2013

2013: 24th Symposium on ALC/MND - Italy, 6-8 December 2013 (2013)$2,500

Funding: University of Tasmania ($2,500)
Scheme: Grant-Conference Support Scheme
Administered By: University of Tasmania
Research Team: King AE
Year: 2013

Determining the mechanism underlying post-operative cognitive decline (2012)$6,508

Funding: Royal Hobart Hospital Research Foundation ($6,508)
Scheme: Grant-Starter
Administered By: University of Tasmania
Research Team: Terblanche N; Blizzard C; King AE; Dickson TC; Skinner MW; Vickers JC
Year: 2012

The role of excitotoxicity in mediating distal axonal degeneration in ALS (2011 - 2013)$379,034

Funding: National Health & Medical Research Council ($379,034)
Scheme: Grant-Project
Administered By: University of Tasmania
Research Team: Dickson TC; Vickers JC; Chung RS; King AE
Period: 2011 - 2013
Grant Reference: 1003931

Myelin loss in Alzheimer's disease (2011 - 2012)$90,000

Funding: Dementia Australia Research Foundation Ltd ($90,000)
Scheme: Fellowship-Postdoctoral Fellowship in Dementia
Administered By: University of Tasmania
Research Team: King AE
Period: 2011 - 2012

The role of muscle-neuron Signaling in Neuromuscular Disease (2011)$15,000

Funding: University of Tasmania ($15,000)
Scheme: Grant-Institutional Research Scheme
Administered By: University of Tasmania
Research Team: King AE
Year: 2011

Nina Buscombe Award Travel Grant (2010)$2,200

Funding: Motor Neurone Disease Victoria ($2,200)
Scheme: Grant-Travel
Administered By: University of Tasmania
Research Team: King AE
Year: 2010

The Role of Distal Axonal Degeneration in Amyotrophic Lateral Sclerosis (Motor Neuron Disease) (2009)$16,583

Funding: University of Tasmania ($16,583)
Scheme: Grant-Institutional Research Scheme
Administered By: University of Tasmania
Research Team: King AE
Year: 2009

The role of distal axonal degeneration in ALS (2009)$27,360

Funding: Motor Neurone Disease Research Australia ($27,360)
Scheme: Grant-In-Aid
Administered By: University of Tasmania
Research Team: King AE; Vickers JC; Dickson TC
Year: 2009

Investigating the causes and consequences of axonal pathology in amyotrophic lateral sclerosis (2008 - 2010)$217,500

Funding: Motor Neurone Disease Research Australia ($217,500)
Scheme: Fellowship-Bill Gole MND Research
Administered By: University of Tasmania
Research Team: King AE
Period: 2008 - 2010

Travel to attend ALS/MND International Symposium in Birmingham 2008 (2008)$5,000

Funding: Motor Neurone Disease Research Australia ($5,000)
Scheme: Grant-Travel
Administered By: University of Tasmania
Research Team: King AE
Year: 2008

Unravelling the cellular pathology underlying neuronal degeneration in motor neuron disease (2007)$24,744

Funding: Motor Neurone Disease Research Australia ($24,744)
Scheme: Grant-in-Aid Zo-ee MND Research
Administered By: University of Tasmania
Research Team: Vickers JC; King AE; Dickson TC; Chung RS; West AK; Chuah MI
Year: 2007

Research Supervision

Professor King is currently seeking PhD students in the following areas

Biomarkers of Brain Health
Axon function and dysfunction in neurodegenerative disease

Current

Completed

Current

Degree	Title	Commenced
PhD	Understanding Axon Pathology in Ageing and Dementia	2020
PhD	Developing Drugs to Protect Neuronal Connections in Neurodegenerative Diseases	2020
PhD	REM Sleep Behaviour Disorder: Prevalence and cognitive characteristics	2020
PhD	Inhibiting Axon Degeneration Through SARM-1 Knockout in Traumatic Brain Injury	2020
PhD	Investigating the Role of SARM1 in Axon Degeneration using Human Induced Pluripotent Stem Cells	2021
PhD	Expanding Our Understanding of Neurofilament Proteins as Biomarkers of Neurodegeneration	2022
PhD	Do Renshaw Cells Drive Disease in ALS?	2022
PhD	Stress hormones and Alzheimer's disease	2023
PhD	Axon Alteration in ALS	2023

Completed

Degree	Title	Completed
PhD	Parvalbumin Interneurons and Perineuronal Nets in Ageing and Neurodegeneration Candidate: Ellie Annemarie Bucher	2023
PhD	Understanding Biological Sex Differences in the Glial Response to Neuropathology after a Traumatic Brain Injury Candidate: Yasmine Victoria Doust	2023
PhD	Developing the Potential of Blood-based Biomarkers for Neurodegenerative Disease Candidate: Md Anisuzzaman Chowdhury	2023
PhD	Human iPSC Genetically Encoded Fluorescent Biosensor Models for Toxicity Imaging Candidate: David Stellon	2023
PhD	The Role of Genetic Factors in Modulating Ageing-related Cognitive Change Candidate: Gongbu Pan	2023
PhD	Strategies for Improving Access to Information Promoting Dementia Risk Reduction Candidate: Hannah Louise Fair	2023
PhD	A Patient-specific Stem Cell Model of Batten Disease Candidate: Sueanne Chear	2022
PhD	Identification of the Oral Microbiome in People with Dementia in Residential Aged Care Candidate: Sangeeta Khadka	2022
PhD	Oligodendrocyte Dysfunction in Dementia and Alzheimer's Disease Candidate: Samuel Dwyer	2021
PhD	Investigations of Excitotoxic Injury in the Visual System of Mice Candidate: James Alexander Bender	2021
PhD	The Impact of Genetic Factors and Cognitive Reserve on Brain Network Organizations of Healthy Elderly Adults Candidate: Manuela Pietzuch	2021
PhD	Targeting Microtubule Alterations in Axon Degeneration and Alzheimer's Disease Candidate: Kelsey Anne Hanson	2019
PhD	Novel Short-Chain Quinones Against Mitochondrial Dysfunction Candidate: Monila Nadikudi	2019
PhD	Frontotemporal Dementia and Amyotrophic Lateral Sclerosis Proteins in Neurite Health and Dysfunction Candidate: Rachel Alice Kathryn Atkinson	2018
PhD	Interneuron Dysfunction in Amyotrophic Lateral Sclerosis Candidate: Rosemary Maree Clark	2017
PhD	Environmental Enrichment for Healthy and Alzheimer's Disease-associated Pathological Ageing Candidate: Kimberley Stuart	2017
PhD	Emtins: Novel Peptides Derived from Metallothionein-II as Potential Therapeutics in Alzheimer's Disease Candidate: Emma Dawn Eaton	2016
PhD	The Effect of Traumatic Brain Injury in Experimental Models of Alzheimer's Disease Candidate: Jessica Marie Collins	2016
PhD	Lab-on-a-Chip Platforms for Understanding Neuronal Cellular Interactions Candidate: Yiing Chiing Yap	2015
PhD	Distal Axon and Neuromuscular Junction Degeneration in Amyotrophic Lateral Sclerosis Candidate: Katherine Adriana Southam	2014
PhD	Role of Neurofilaments in Ageing and Neurodegenerative Disease Candidate: Yao Liu	2013
PhD	Axonal and Synaptic Pathology in Alzheimer's Disease Candidate: Stanislaw Mitew	2013
PhD	Alpha-synuclein in the Neurodegenerative Mechanisms of Parkinson's Disease and Dementia with Lewy Bodies Candidate: Ruth Elizabeth Joy Musgrove	2012
PhD	The Response of the Mature Central Nervous System to Traumatic Brain Injury Candidate: Catherine Anne Blizzard	2011